LogoDivision of Infectious Diseases

Untitled Document
Home
Faculty
ID Conference Calendar
Fellowship Program
Hospital Epidemiology and Infection Prevention
Transplant ID Program
Research
HIV/AIDS Program
HIV Prevention and
Treatment Research
Clinical References
Antibiotic Stewardship Program
Travel Medicine
Referral
Home
Faculty
ID Conference Calendar
Fellowship Program
Hospital Epidemiology and Infection Prevention
Transplant ID Program
Research
HIV/AIDS Program
Clinical References
Antibiotic Stewardship Program
Travel Medicine
Referral
Contact us
 
Scott M. Hammer Rachel Gordon Michael Parry
Karen Brudney Sandra Hyman Marcus Pereira
Mary Ann Chiasson Jessica Justman Deborah Rudin
Phyllis Della-Latta Charles Knirsch Mathew Scherer
Jay Dobkin Christine J. Kubin Brian Scully
Tanya Ellman Franklin Lowy Noga Shalev
David A. Fidock Wendy McGahee Magdalena Sobieszczyk
Mary Flood Benjamin Miko Angela Gomez-Simmonds
E. Yoko Furuya Ellen Morrison Hong Van Tieu
Claire Gordon Julie Myers Barbara Taylor
Peter Gordon Susan Olender Anne-Catrin Uhlemann
    Michael Yin
 

Scott M. Hammer, MD

NAME: Scott M. Hammer, MD

ACADEMIC TITLE:
Chief, Division of Infectious Diseases
Harold C. Neu Professor of Medicine
Professor of Epidemiology

EDUCATION:
Columbia College, BA, 1968
Columbia University College of Physicians and Surgeons, MD, 1972

SPECIALTY: HIV pathogenesis, therapy, and vaccine development

RESEARCH SUMMARY: Dr. Hammer is the Harold C. Neu Professor of Medicine, Professor of Epidemiology and Chief of the Division of Infectious Diseases at the NewYork-Presbyterian/Columbia University Medical Center (NYP-CUMC). Dr. Hammer’s major investigative interest is the treatment and prevention of HIV disease. He is an investigator in the National Institutes of Health sponsored AIDS Clinical Trials Group (ACTG), a multicenter organization which performs clinical trials designed to improve the understanding and treatment of HIV infection and its complications. As an ACTG investigator, Dr. Hammer chaired the two largest national trials of antiretroviral therapy carried out by that group in the 1990’s, studies which contributed to the current standard of care of HIV infection. In addition to his interest in the treatment of persons with established HIV infection, Dr. Hammer is an investigator in the National Institutes of Health sponsored HIV Vaccine Trials Network (HVTN), a multicenter organization whose mission is to develop an effective preventive HIV vaccine. He is the current protocol chair of HVTN 505, an advanced phase II study of the preventive HIV vaccine regimen developed by NIAID’s Vaccine Research Center. He is a former Chair of the AIDS Vaccine Research Working Group of the Division of AIDS, NIAID, and the Antiviral Products Advisory Committee of the Food and Drug Administration and currently serves on the Editorial Board of the New England Journal of Medicine. Dr. Hammer is a former Chair of the International AIDS Society-USA’s Antiretroviral Guidelines Panel and former Vice Chair of the World Health Organization’s Strategic and Technical Advisory Committee for HIV/AIDS. He chaired the Guidelines Development Group of the WHO’s Antiretroviral Guidelines for Resource Limited Settings in 2002, 2003 and 2006 and co-chaired the Steering Committee of the WHO’s Global HIV Drug Resistance Surveillance Program. In his role as Chief of the Division of Infectious Diseases at CUMC, he is dedicated to fellow and faculty growth and to the development of state-of-the-art infection surveillance at the institutional and regional levels to improve and protect the public health.

SELECTED PUBLICATIONS:
Hansom B, Janes HE, Guarino PD, Huang Y, Brown ER, Chen YO, Hammer SM, Gilbert PB, Donnell DJ. Preventing HIV-1 Infection in Women using Oral Pre-Exposure Prophylaxis: A Meta-Analysis of Current Evidence. J Acquir Immune Defic Syndr. 2016 Aug 16. [Epub ahead of print].

Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A, McElrath MJ, Corey L, Mascola JR, Graham BS, Sobieszczyk ME, Kublin JG, Robertson M, Hammer SM, Gray GE, Buchbinder SP, Gilbert PB. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. PLoS ONE. 2015; 10(9): e0136626.

Dawson L, Garner S, Anude C, Ndebele P, Karuna S, Holt R, Broder G, Handibode J, Hammer SM, Sobieszczyk ME. Testing the Waters: Ethical Considerations for including PrEP in a phase IIb HIV vaccine efficacy trial. NIAID HIV Vaccine Trials Network. Clin Trials. 2015 Aug;12(4):394-402. doi: 10.1177/1740774515579165. Epub 2015 Apr 7.

Williams WB, Liao HX, Moody MA, Kepler TB, Alam SM, Gao F, Wiehe K, Trama AM, Jones K, Zhang R, Song H, Marshall DJ, Whitesides JF, Sawatzki K, Hua A, Liu P, Tay MZ, Seaton KE, Shen X, Foulger A, Lloyd KE, Parks R, Pollara J, Ferrari G, Yu JS, Vandergrift N, Montefiori DC, Sobieszczyk ME, Hammer S, Karuna S, Gilbert P, Grove D, Grunenberg N, McElrath MJ, Mascola JR, Koup RA, Corey L, Nabel GJ, Morgan C, Churchyard G, Maenza J, Keefer M, Graham BS, Baden LR, Tomaras GD, Haynes BF. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science. 2015 Aug 14;349(6249):aab1253. doi: 10.1126/science.aab1253. Epub 2015 Jul 30. PMID: 26229114

Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, Hural J, DeRosa SC, Kalams SA, McElrath MJ, Keefer MC, Baden LR, Lama JR, Sanchez J, Mulligan MJ, Buchbinder SP, Hammer SM, Koblin BA, Pensiero M, Butler C, Moss B, and Robinson HL. Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles. The Journal of Infectious Diseases. 2014;210:99–110

Frey SE, Peiperl L, McElrath MJ, Kalams S, Goepfert PA, Keefer MC, Baden LR, Lally MA, Mayer K, Blattner WA, Harro CD, Hammer SM, Geoffrey J. Gorse, John Hural, Georgia D. Tomaras, Yves Levy, Peter Gilbert, Allan deCamp, Nina D. Russell, Marnie Elizaga, Mary Allen, Lawrence Corey. Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants. Clin Vaccine Immunol November 2014 vol. 21 no. 11 1589-1599

Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ, Keefer MC, Baden LR, Swann EM, Grant S, Ahmed H, Li F, Hertz T, Self SG, Friedrich D, Frahm N, Liao HX, Montefiori DC, Tomaras GD, McElrath MJ, Hural J, Graham BS, Jin X. Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.; HVTN 083 Study Group and the NIAID HVTN. Infect Dis. 2016 Feb 15;213(4):541-50. doi: 10.1093/infdis/jiv496. Epub 2015 Oct 15.

Hammer SM. Baby steps on the road to HIV eradication. N Engl J Med. 2013 Nov 7;369(19):1855-7. doi: 10.1056/NEJMe1309006. Epub 2013 Oct 23.

Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB; Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. HVTN 505 Study Team. N Engl J Med. 2013 Nov 28;369(22):2083-92. doi: 10.1056/NEJMoa1310566. Epub 2013 Oct 7.

Tieu HV, Rolland M, Hammer SM, Sobieszczyk ME. Translational Research Insights from Completed HIV Vaccine Efficacy Trials. Accepted Journal of AIDS 2013; (63) Supplement 2, July 1

Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk MS, and Hammer SM. In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Nonvaccine Prevention Modalities. AIDS Research and Human Retroviruses 2013. ahead of print. doi:10.1089/aid.2012.0385

Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012 Jul 25;308(4):387-402.

Brehm JH, Scott Y, Koontz DL, Perry S, Hammer S, Katzenstein D, Mellors JW, Sluis-Cremer N; AIDS Clinical Trials Group Study 175 Protocol Team. Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase. PLoS One. 2012;7(2):e31558.

Pine SO, Kublin JG, Hammer SM, Borgerding J, Huang Y, Casimiro DR, McElrath MJ. Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans. PLoS One. 2011 Apr 13;6(4):e18526.

Gilbert PB, Berger JO, Stablein D, Becker S, Essex M, Hammer SM, Kim JH, Degruttola VG. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis. 2011 Apr 1;203(7):969-75.

Hammer SM. Antiretroviral treatment as prevention. N Engl J Med. 2011 Aug 11;365(6):561-2.

Hammer SM, Ribaudo H, Bassett R, Mellors JW, Demeter LM, Coombs RW, Currier J, Morse GD, Gerber JG, Martinez AI, Spreen W, Fischl MA, Squires KE; AIDS Clinical Trials Group (ACTG) 372A Study Team. A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. HIV Clin Trials. 2010 Nov-Dec;11(6):312-24.

Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, Gray G, Pape J, Robertson MN, Mehrotra DV, Self S, Turner K, Sanchez J, Pitisutithum P, Duerr A, Dubey S, Kierstead L, Casimiro, D and Hammer SM for the Merck V520-018/HIV Vaccine Trials Network 050 Study Team:  Safety and immunogenicity of the MRKAd5 gag HIV type 1 vaccine in a worldwide phase 1 study of healthy adults.  AIDS Res Hum Retroviruses 2010;Nov 23 (epublished ahead of print). 

Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Günthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010 Jul 21;304(3):321-33.

Montaner JS, Richman DD, Hammer SM; International AIDS Society-USA Antiretroviral Guidelines Panel. Poor agreement between 2 assays for measuring low levels of HIV-1 viral load. Clin Infect Dis. 2009 Oct 15;49(8):1283-4.

Castor D, Vlahov D, Hoover DR, Berkman A, Wu YF, Zeller B, Brechtl J, Hammer SM. The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART. J Med Virol. 2009 Aug;81(8):1323-35.

Coovadia A, Hunt G, Abrams EJ, Sherman G, Meyers T, Barry G, Malan E, Marais B, Stehlau R, Ledwaba J, Hammer SM, Morris L, Kuhn L. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis. 2009 Feb 15;48(4):462-72.

Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, Martin M, Overbaugh J, Watkins DI, Mahmoud A, Greene WC. HIV vaccine research: the way forward. Science. 2008 Jul 25;321(5888):530-2.

Demeter LM, DeGruttola V, Lustgarten S, Bettendorf D, Fischl M, Eshleman S, Spreen W, Nguyen BY, Koval CE, Eron JJ, Hammer S and Squires K: Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials 2008;9:11-25.

Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JSG, Richman DD, Yeni PG and Volberding PA: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society – USA Panel. JAMA 2008; 300:555-570.

Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008 Jul 15;47(2):266-85.

Taylor BS, Sobieszczyk ME, McCutchan FE and Hammer SM: The challenge of HIV-1 subtype diversity. NEJM 2008;358:1590-1602.

Hammer S, Riley A, Calmy A, Harries A, Duncombe C, Havlir D, Katabira E, Scano F, Malkin JE, Lange J, Mukerjee J, Currier J, Mofenson L, Harrington M, Schechter M, Kumarasamy N, Sow PS, Munderi P, Ojoo S, Cahn P, Phanuphak P, Eholie S, El Sadr W, Rodriguez W: Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach 2006 revision. World Health Organization, August 2006, available at www.who.int.

Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society--USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med. 2006;14:827-43.

Gripshover BM, Ribaudo H, Santana J, Gerber JG, Campbell TB, Hogg E, Jarocki B, Hammer SM, Kuritzkes DR; A5118 Team. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006;11:619-23.

Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society--USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. JAMA 2006;296:827-43.

Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC (for the ACTG 175 study team). A trial of nucleoside monotherapy vs. combination therapy in HIV-infected adults with CD4 cell counts between 200 and 500 per cubic millimeter: NIAID-sponsored AIDS clinical trials group study 175. N Engl J Med. 1996;335:1081-1096.

Sobieszczyk ME, Jones J, Wilkin T, Hammer SM. Advances in antiretroviral therapy. Top HIV Med. 2006;14:36-62.

Hammer SM. Clinical practice. Management of newly diagnosed HIV infection. N Engl J Med. 2005;353:1702-1710.

Hammer SM, Mofenson L, Havlir D, Vitorio M, Perriens J and the WHO Writing Committee: Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2003 version. World Health Organization, December 2003, available at www.who.int.

Hammer SM, Bassett R, Squires KE, Fischl M, Demeter LM, Currier JS, Mellors JW, Morse GD, Eron JJ, Santana JL, and DeGruttola V. A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antivir Ther. 2003;8:507-518.

Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, and Mellors JW (for the AIDS clinical trials group 398 study team). Dual vs. single protease inhibitor therapy following antiretroviral treatment failure: A randomized trial. J Am Med Assoc. 2002;288:169-180.

Hammer S, Gibb D, Havlir D, Mofenson L, VAn Beek I, Vella S, Vareldzis B, Perriens J and the WHO Writing Committee: Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. World Health Organization, April 2002, available at www.who.int.

Hammer SM. Increasing choices for HIV therapy. N Engl J Med. 2002;346:2022-2023.

Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 2: Genetic factors and implications for antiretroviral therapeutics. Ann Intern Med. 2001;134:978-996.

Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 1: Cellular and humoral immune responses. Ann Intern Med. 2001;134:761-776.

Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA (for the AIDS clinical trials group 320 study team). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.

OFFICE INFORMATION:
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Tel: (212) 305-7185
Fax: (212) 305-7290
E-mail: smh48@columbia.edu

 

Back to Top

 

NAME: Karen Brudney, MD

ACADEMIC TITLE:
Assistant Clinical Professor of Medicine

EDUCATION:
Yale University, BA, 1973
Columbia University College of Physicians and Surgeons, MD, 1980

SPECIALTY: Tuberculosis, HIV therapy, HIV primary care, patient adherence and access to care

RESEARCH SUMMARY: Dr. Brudney is currently the Senior Expert Adviser to the Centers for Disease Control Division of HIV and Tuberculosis. She spends a significant amount of time working in the southern cone of Africa—Mozambique, Zimbabwe and Zambia—on HIV and Tuberculosis. She has also worked on TB Infection Control issues in Mumbai and is currently involved in a new project on MDRTB there.

Dr. Brudney was the program director for the Treatment Adherence Demonstration Project in the Comprehensive HIV Program Outpatient HIV clinic. In order to improve antiretroviral adherence in difficult populations, an interdisciplinary program called Jumpstart was initiated in 1998 in the Infectious Disease/AIDS Clinic at NewYork–Presbyterian Hospital.

Dr. Brudney obtained a 5 year NIH Fogarty grant for research training in 2002 and trained several teams of Dominican health professionals in the HIV care and delivery program in Santo Domingo, Dominican Republic.

SELECTED PUBLICATIONS:
Gomes A, Reyes EV, Garduno LS, Rojas R, Mir Mesejo G, Del Rosario E, Jose L, Javier C, Vaughan C, Donastorg Y, Hammer S, Brudney K, Taylor BS. Incidence of Diabetes Mellitus and Obesity and the Overalp of Comorbodities in HIV+ Hispanics Initiating Antiretroviral Therapy. PLoS One. 2016 Aug 10;11(8):e0160797. eCollection 2016.

Frieden TR, Brudney KF, Harries AD. “Global Tuberculosis: Perspectives, Prospects and Priorities.: JAMA 312: 1393-4; 2014

Taylor B, Reyes E, Levie EA, Khan L, Garduno LS, Donastorg Y, Hammer, Brudney K, Hirsch JS. “Patterns of Geographic Mobility Predict Barriers to Engagement in HIV Care and Antiretroviral Treatment Adherence.” AIDS Patient Care and STDs 28:1-12; 2014.

Bassett MT, Brudney K. Treating our way out of AIDS? Am J Public Health. 2014 Feb;104(2):200-3. Epub 2013 Dec 12.

Bassett MT, Brudney K. WHO's new guidelines for antiretroviral treatment. Lancet. 2013 Nov 30;382(9907):1777-8.

Myers JE, Taylor BS, Rojas Fermín RA, Reyes EV, Vaughan C, José L, Javier C, Franco Estévez R, Donastorg Cabral Y, Batista A, Lie Y, Coakley E, Hammer SM, Brudney K. “Transmitted Drug Resistance Among Antiretroviral-Naive Patients with Established HIV Type 1 Infection in Santo Domingo, Dominican Republic and Review of the Latin American and Caribbean Literature.” AIDS Res Hum Retroviruses. 28:667-74, 2012.

Taylor BS, Garduño LS, Reyes EV, Valiño R, Rojas R, Donastorg Y, Brudney K, Hirsch J. HIV care for geographically mobile populations. Mt Sinai J Med. 2011 May-Jun;78(3):342-51. Review.

Furuya EY, Paez A, Srinivasan A, Cooksey R, Augunbraun M, Baron M, Brudney K, Della-Latta P, Concepcion E, Fischer S, Flood M, Kellner P, Roman C, Yakrus M, Weiss D, Granowitz EV. “Outbreak of Mycobacterium abscessus wound infections among ‘Lipotourists’ from the United States who underwent abdominoplasty in the Dominican Republic.” Clinical Infectious Diseases 46:1181-8; 2008.

Yin M, Dobkin JF, Brudney KF, Becker C, Zadel JL, Manandhar M, Addesso-Dodd V, Shane E. Bone mass and mineral metabolism in HIV-infected postmenopausal women. Osteoporos Int. 2005;16:1345-1352.

Wilkin TJ, Palmer S, Brudney KF, Chiasson MA, Wright TC. Anal intraepithelial neoplasia in heterosexual and homosexual HIV-positive men with access to anti-retroviral therapy. J Infect Dis. 2004;190:1685-1691.


OFFICE INFORMATION:
Harkness Pavilion, 6th Floor
180 Fort Washington Avenue
New York, NY 10032
Tel: 212-305-7068
Fax: 212-305-7692
E-mail: kfb2@columbia.edu

 

Back to Top

 

http://www.cumc.columbia.edu/dept/id/images/spacer.gif

NAME: Mary Ann Chiasson, MS, MPH, DrPH


ACADEMIC TITLE:
Professor of Clinical Epidemiology (in Medicine)

EDUCATION:
Bennington College, BA, 1972

New York University, MS, 1978

Columbia University Mailman School of Public Health, MPH, 1985
Columbia University Mailman School of Public Health, DrPH, 1988

SPECIALTY: Epidemiology of HIV, HPV, and other STIs; reproductive health

RESEARCH SUMMARY: Dr. Mary Ann Chiasson is an epidemiologist with a part-time faculty appointment in the Division of Infectious Diseases. Her primary appointment is in the Epidemiology Division at Columbia's Mailman School of Public Health where she has co-directed the Epidemiology of HIV/AIDS course since 1989. Dr. Chiasson has been the vice president for research and evaluation at Public Health Solutions since 1999. Before joining Public Health Solutions, she served for nine years as an assistant commissioner of health at the New York City Department of Health with scientific and administrative responsibility for AIDS surveillance, HIV/AIDS research, and vital statistics and epidemiology. Dr. Chiasson's research interests include the epidemiology of HIV (particularly risk factors for sexual transmission), women's reproductive health, and early childhood obesity. Since 2001 her HIV-related research has focused on the relationship between the Internet and high risk sexual behavior among men who have sex with men (MSM) and how the Internet and other digital media can be harnessed for delivery of HIV and other health-related prevention interventions. The online HIV prevention videos produced by the research collaboration she leads can be viewed at http://www.hivbigdeal.org/.

SELECTED PUBLICATIONS:
Hirshfield S, Grove C, Parsons JT, Anderson I, Chiasson MA. Social media use and HIV transmission risk behavior among ethnically diverse HIV-positive gay men: results of an online study in three US cities. Arch Sex Behav. 2015Jul 16. [Epubb ahead of print] PMID: 2619596

Hirshfield S, Scrimshaw EW, Stall RD, Margolis AD, Downing MJ Jr, Chiasson MA. Drug use, sexual risk, and syndemic production among men who have sex with men who engage in group sexual encounters. Am J Public Health. 2015 Sep;105(9):1849-58. Doi: 10.2015/AJPH.2014.302346. Epub 2015 Feb 25. PMID: 25713951

Grov C, Hirshfield S, Remien RH, Humberstone M, Chiasson MA. Exploring the venue's role in risky sexual behavior among gay and bisexual men: An event-level analysis from a national online survey in the U.S. Archives of Sexual Behavior. 2013 Feb;42(2):291-302.

Garbers S, Meserve A, Kottke M, Hatcher RA, Chiasson MA.  Contraceptive history, unintended pregnancy and contraceptive method choice among urban low-income women. Journal of Women’s Health. 2013 Sep 13. [Epub ahead of print].

Chiasson MA, Findley SE, Sekhobo JP, Scheinmann R, Edmunds LS, Faly AS, McLeod NJ. Changing WIC changes what children eat. Obesity (Silver Spring). 2013 Jul;21(7):1423-9. doi: 10.1002/oby.20295. Epub 2013 May 22. PMID: 23703806

Margolis AD, Joseph H, Belcher L, Hirshfield S, Chiasson MA. ‘Never testing for HIV’ among men who have sex with men recruited from a sexual networking website, United States. AIDS Behav. 2012 Jan;16(1):23-9.

Taylor BS, Chiasson MA, Scheinmann R, Hirshfield S, Humberstone M, Remien RH, Wolitski RJ, Wong T. Results from two online surveys comparing sexual risk behaviors in Hispanic, Black, and White men who have sex with men. AIDS and Behavior. 2012 Apr;16(3):644-52. 2011 June 21 [Epub ahead of print].

Garbers S, Meserve A, Kottke M, Hatcher RA, Ventura A, Chiasson MA. Randomized controlled trial of a computer-based module to improve contraceptive method choice. Contraception. 2012 Oct; 86(4):383-90. Doi: 10. 1016/j.Mar 6 [Epub ahead of print]

Garbers S, Meserve A, Kottke M, Hatcher RA, Ventura A, Chiasson MA. Tailored health messaging improves contraceptive continuation and adherence: Results from a randomized controlled trial. Contraception. 2012 Nov; 86(5):536-42. Doi: 10.1016/j; Mar 23 [Epub ahead of print]

Hirshfield S, Chiasson MA, Joseph H, Scheinmann R, Johnson WD, Remien RH, Shaw FS, Emmons R, Yu G, and Margolis AD. An Online Randomized Controlled Trial Evaluating HIV Prevention Digital Media Interventions for Men who have Sex with Men. PLoS One 2012, 7(10): e46252. doi:10.1371/journal.pone.0046252. Epub 2012 Oct 2.


OFFICE INFORMATION:
Public Health Solutions
40 Worth Street, 5th Floor
New York, NY 10013-2988
Tel: 646-619-6411
Fax: 646-619-6777
E-mail: machiasson@healthsolutions.org

 

Back to Top

 

Jay Dobkin, MD

NAME: Jay Dobkin, MD

ACADEMIC TITLE:
Arnold P. Gold Foundation Associate Professor of Clinical Medicine


EDUCATION:
Columbia College, BA, 1968
Dartmouth Medical School, BMS, 1970
Harvard Medical School, MD, 1972

SPECIALTY: Antiretroviral therapy, harm reduction

RESEARCH SUMMARY:
Dr. Jay Dobkin is the Arnold P. Gold Foundation Associate Professor of Clinical Medicine. Dr. Dobkin is the director of the AIDS program at Columbia University Medical Center. He is the principal investigator of an ongoing series of quantitative assessments of interventions to promote improved adherence to antiretroviral therapy. Dr. Dobkin is also developing assessment strategies for antiretroviral treatment programs targeting injection drug users in the former Soviet Union in collaboration with several nongovernmental organizations active in these areas including the Open Society Institute (New York) and the Open Health Institute (Moscow). He serves as a consultant to the World Health Organization on care and treatment of HIV-infected injection drug users. He is involved in research examining the pathogenesis of HIV-associated bone loss in a longitudinal cohort of postmenopausal women. Dr. Dobkin is also the principal investigator of several industry-sponsored studies of new antiretroviral agents.

SELECTED PUBLICATIONS:
Dobkin J. Preventing pneumococcal disease. AIDS Reader. 2006. 16(2):81-2 AIDS Read. 2006 Feb;16(2):81-2.

Yin M, Dobkin JF, Brudney KF, Becker C, Zadel JL, Manandhar M, Addesso-Dodd V, Shane E. Bone mass and mineral metabolism in HIV-infected postmenopausal women. Osteoporos Int. 2005;16:1345-1352.

Bangsberg D et al. Reduction in tuberculin skin-test conversions among medical house staff associated with improved tuberculosis infection control practices. Infect Control Hosp Epidemiol. 1998;18:566-570.

Simpson D et al. Peptide T in the treatment of painful distal neuropathy associated with AIDS: Results of a placebo-controlled trial. Neurology. 1996;44:1254-1259.

Lutfey M et al. Independent origin of mono-rifampin-resistant mycobacterium tuberculosis in patients with AIDS. Am J Respir Crit Care Med. 1996;153:837-840.

Thomas C, Dobkin JF, Weinberger O. TAT-medicated transcellular activation of HIV-1 long terminal repeat directed gene expression by HIV-1 infected peripheral blood mononuclear cells. J Immunology. 1994;153:3831-3839.

Gormam JM et al. Development and characteristics of a medical staging system for HIV infection. Int J Methods Psychiatr Res. 1993;2:117-124.

Brunswick A et al. HIV-1 seroprevalence and risk behaviors in an urban African American community cohort. Am J Public Health. 1993;83:1390-1394.

Cohn D, Dobkin JF. Treatment and prevention of tuberculosis in HIV infection. AIDS. 1993;7(suppl 1):S195-S202.


OFFICE INFORMATION:
Harkness Pavilion, 6th Floor
180 Fort Washington Avenue
New York, NY 10032
Tel: 212-305-8507
Fax: 212-305-7692
E-mail: Jfd2@columbia.edu

 

Back to Top

 
   

http://cait.columbia.edu:88/dept/id/images/spacer.gif

NAME: Tanya Ellman, MD, MS

ACADEMIC TITLE:
Instructor in Clinical Medicine

EDUCATION:
Wesleyan University, BA, 2001
Weill Medical College of Cornell University, MD, 2007
Columbia University Mailman School of Public Health, MS in Epidemiology, 2013

SPECIALTY: HIV epidemiology, prevention, and clinical care, International HIV

RESEARCH SUMMARY:Dr. Ellman is an Instructor in Clinical Medicine in the Division of Infectious Diseases.  She also holds the position of Associate Research Scientist at ICAP, which, based in the Mailman School of Public Health, provides implementation and technical assistance for HIV and related health programs across Africa and Central Asia.  In her role there as Adult HIV Care and Treatment Clinical Officer, she provides technical guidance to in-country staff, supports implementation of HIV programs, conducts clinical, implementation science, and epidemiological research in HIV and related disorders, and works at the Bronx Prevention Center on HIV prevention studies.  Dr. Ellman’s primary research interests include late HIV diagnosis and delayed entry to care, particularly in older adults, aggregate HIV viral load measurements as a tool for monitoring HIV epidemics, implementation of viral load monitoring in resource limited settings, and modes of PrEP delivery including in resource limited settings and long acting formulations.

SELECTED PUBLICATIONS:
Ramaswamy C, Ellman TM, Myers J, Madsen A, Sepkowitz K, Shepard C. Human Immunodeficiency Virus Infection Newly Diagnosed at Autopsy in New York City, 2008-2012. Open Forum Infect Dis. 2015; 2(4):ofv146.

Ellman TM, Hawkins K, Benitez J, Negron R, Chang S, Palmer S, Robertson V, Chiasson MA, Sobieszczyk ME. Representation of Latinos and Blacks in screening for and enrollment into preventive HIV vaccine trials in New York City. Vaccine 2015; 33(48):6809-15.

Saito S, Howard AA, Chege D, Ellman TM, Ahoua L, Elul B, Rabkin M. Monitoring quality at scale: implementing quality assurance in a diverse, multicountry HIV program. AIDS 2015; Suppl 2:S129-36.

Ellman TM, Emerson R, Donnell D, Philip N, Nkambule R, Bock N, Ehrenkranz P, Bicego G, Justman J. Awareness of HIV diagnosis in the Swaziland HIV Incidence Measurement Survey (SHIMS). Abstract #1013, Conference on Retroviruses and Opportunistic Infections, 2015

Myers JE, Ellman TM, Westhoff C. Injectable agents for pre-exposure prophylaxis: lessons learned from contraception to inform HIV prevention. Curr Opin HIV AIDS 2015; 10:271-7.

Ellman TM, Sexton ME, Warshafsky D, Sobieszczyk ME, Morrison EAB. A forgotten population: older adults with newly-diagnosed HIV. AIDS Patient Care and STDs 2014; 28:530-536.

El-Sadr W, Okello V, McNairy M, Ellman T, Kidane A, Bongomin P, Kamiru H, Justman J, Sahabo R. Use of routine data to monitor, evaluate and enhance programs – Swaziland. Session WESA04, 20th International AIDS Conference, 2014

Justman J, Ellman T, Donnell D, Duong Y, Reed J, Bicego G, Ehrenkranz P, Wang L, Bock N, Nkambule R. Population HIV viral load estimate in Swaziland: assessing ART program effectiveness and transmission potential. Abstract #96, Conference on Retroviruses and Opportunistic Infections, 2013

Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MY. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. Journal of Infection 2012; 65: 80-87.

Kapur A, Tang EC, Van Tieu H, Koblin BA, Ellman TM, Sobieszczyk ME. Knowledge, attitudes, and willingness of New York City (NYC) providers to prescribe oral pre-exposure prophylaxis (PrEP) for HIV prevention. Abstract WEPE273, XIX International AIDS Conference, 2012

OFFICE INFORMATION:
Columbia University Medical Center
630 West 168th Street P&S Box 82
New York, NY 10032
Tel: 212-342-3767
Fax: 212-342-1824
E-mail: tme2108@cumc.columbia.edu

 

Back to Top

 

 

Fidock

Fidock D

NAME: David A. Fidock, PhD

ACADEMIC TITLE:

Professor of Microbiology & Immunology and of Medical Sciences in Medicine

EDUCATION:
Adelaide University, South Australia B.Sc., 1986

University Paris VII, France, Ph.D., 1994

SPECIALTY: Malaria drug resistance, chemotherapy, drug discovery, pathogenesis, fatty acid metabolism, cell development


RESEARCH SUMMARY: Biological investigations into Plasmodium falciparum, the etiologic agent of severe malaria, reveal an organism that is tremendously adept at overcoming therapeutic attack and evading host immunity. This haploid Apicomplexan parasite causes disease in over 220 million individuals and kills over 440,000 African children yearly, and prevents sterilizing immunity from being acquired even by individuals who have been infected thousands of times. Disease can result from severe anemia, hyperparasitemia, or other complications resulting from sequestration of parasitized red blood cells (RBC) in the microvasculature, a process that depends on the presentation of antigenically distinct parasite proteins on the infected RBC surface. Chemotherapeutic clearance of asexual blood stage parasites is the linchpin of malaria treatment and control, however it is systematically thwarted by the acquisition of resistance. The most dramatic consequence has been with chloroquine (CQ), for decades the gold standard until resistance appeared and pre-empted a dramatic increase in malaria mortality and morbidity rates, particularly in Africa.

During my past 27 years of malaria research, I have studied how P. falciparum invades and develops within hepatocytes and RBC, what immune effector mechanisms operate on these stages, how antimalarials act and how parasites counter their action, and how parasites are successfully transmitted to Anopheles mosquitoes, their definitive host. My laboratory’s ongoing and planned research channels these interests into several themes: 1) What are the parasite factors that mediate resistance to antimalarial drugs; 2) What biological processes are targeted by antimalarial drugs and what accounts for parasite death; 3) What biochemical and physiological functions are intrinsic to the digestive vacuole and the apicoplast, the site of action of CQ and of antibiotics respectively; and 4) How does P. falciparum regulate its virulence and prevent the establishment of protective immunity. These studies benefit from our extensive experience in P. falciparum transfection and we constantly strive for new innovations in genetics to enhance the power of these investigations.

SELECTED PUBLICATIONS:
Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gnädig N, Uhlemann AC, Martin RE, Lehane AM and Fidock DA (2016). Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies. Nature Commun. 7: 11553.

Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gnädig N, Uhlemann AC, Martin RE, Lehane AM and Fidock DA (2016). Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies. Nature Commun. 7: 11553.

Ng CL, Siciliano G, Lee MC, de Almeida MJ, Corey VC, Bopp SE, Bertuccini L, Wittlin S, Kasdin RG, Le Bihan A, Clozel M, Winzeler EA, Alano P and Fidock DA (2016). CRISPR-Cas9-modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazine-containing compounds but potentiates artemisinin-based combination therapy partner drugs. Mol. Microbiol. 101: 381-93.

Gabryszewski SJ, Modchang C, Musset L, Chookajorn T and Fidock DA (2016). Combinatorial genetic modeling of pfcrt-mediated drug resistance evolution in Plasmodium falciparum. Mol. Biol. Evol. 33: 1554-70.

Gulati S, Ekland EH, Ruggles KV, Chan RB, Jayabalasingham B, Zhou B, Mantel PY, Lee MC, Spottiswoode N, Coburn-Flynn O, Hjelmqvist D, Worgall TS, Marti M, Di Paolo G and Fidock DA (2015). Profiling the essential nature of lipid metabolism in asexual blood and gametocyte stages of Plasmodium falciparum. Cell Host Microbe 18: 371-81.

Petersen I, Gabryszewski SJ, Johnston GL, Dhingra SK, Ecker A, Lewis RE, de Almeida MJ, Straimer J, Henrich PH, Palatulan E, Johnson DJ, Coburn-Flynn O, Sanchez C, Lehane AM, Lanzer M & Fidock DA (2015). Balancing drug resistance and growth rates via compensatory mutations in the Plasmodium falciparum chloroquine resistance transporter. Mol. Microbiol. 97: 381-95.

Straimer J, Gnadig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, Dacheux M, Khim N, Zhang L, Lam S, Gregory PD, Urnov FD, Mercereau-Puijalon O, Benoit-Vical F, Fairhurst RM, Menard D & Fidock DA (2015). Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science 347: 428-31.

Lisewski AM, Quiros JP, Ng CL, Adikesavan AK, Miura K, Putluri N, Eastman RT, Scanfeld D, Regenbogen SJ, Altenhofen L, Llinas M, Sreekumar A, Long C, Fidock DA & Lichtarge O (2014). Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate. Cell 158: 916-28.

Johnston GL, Gething PW, Hay SI, Smith DL and Fidock DA (2014). Modeling within-host effects of drugs on Plasmodium falciparum transmission and prospects for malaria elimination. PLoS Comp. Biol. 10: e1003434.

Falkard B, Kumar TR, Hecht LS, Matthews KA, Henrich PP, Gulati S, Lewis RE, Manary MJ, Winzeler EA, Sinnis P, Prigge ST, Heussler V, Deschermeier C and Fidock DA (2013). A key role for lipoic acid synthesis during Plasmodium liver stage development. Cell. Microbiol. 15: 1585-1604.

McNamara CW, Lee MC, Lim CS, Lim SH, Roland J, Nagle A, Simon O, Yeung BK, Chatterjee AK, McCormack SL, Manary MJ, Zeeman AM, Dechering KJ, Kumar TR, Henrich PP, Gagaring K, Ibanez M, Kato N, Kuhen KL, Fischli C, Rottmann M, Plouffe DM, Bursulaya B, Meister S, Rameh L, Trappe J, Haasen D, Timmerman M, Sauerwein RW, Suwanarusk R, Russell B, Renia L, Nosten F, Tully DC, Kocken CH, Glynne RJ, Bodenreider C, Fidock DA, Diagana TT and Winzeler EA. Targeting Plasmodium PI(4)K to eliminate malaria. Nature 504: 248-253.

Fidock DA (2013). Eliminating malaria. Science 340: 1531-1533.

Straimer J, Lee MC, Lee AH, Zeitler B, Williams AE, Pearl JR, Zhang L, Rebar EJ, Gregory PD, Llinas M, Urnov FD and Fidock DA (2012). Site-specific genome editing in Plasmodium falciparum using engineered zinc-finger nucleases. Nature Methods 9: 993-8.

Uhlemann AC and Fidock DA (2012). Loss of malarial susceptibility to artemisinin in Thailand. The Lancet 379: 1928-30.

Adjalley SH, Johnston G, Li T, Eappen AG, Eastman RT, Ekland EH, Richman A, Sim BKL, Lee MCS, Hoffman SL and Fidock DA (2011). Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity of the synthetic dye methylene blue. Proc. Natl. Acad. Sci. USA 108: E1214-23.

Eastman RE and Fidock DA (2009). Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nature Rev. Microbiol. 7: 864-74.

Yu M, Kumar TR, Nkrumah LJ, Coppi A, Retzlaff S, Li CD, Kelly BJ, Moura PA, Lakshmanan V, Freundlich JS, VAlderramos JC, Vicheze C, Siedner M, Tsai JH, Flkard B, Sidhu AB, Purcell LA, Gratraud P, Kremer L, Waters AP, Schiehser, G, Jacobus DP, Janse CJ, Ager A, Jacobs WR Jr, Sacchettini JC, Heussler V, Sinnis P and Fidock DA (2008). The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host & Microbe 4: 567-78.

LABORATORY HOMEPAGE:
http://www.microbiology.columbia.edu/fidock/


OFFICE INFORMATION:
Department of Microbiology and Immunology,
Hammer Health Sciences Center, Room 1502
701 West 168th Street
New York, NY 10032
Tel: (212) 305-0816
Fax: (212) 305-4038
Email: df2260@columbia.edu

 
 

 

Mary Flood, MD, PhD

Flood

NAME: Mary T. Flood, MD, PhD

ACADEMIC TITLE:
Associate Clinical Professor of Medicine


EDUCATION:
Dominican College of Blauvelt, BS, 1968
New York University, PhD, 1976
Teachers College, Columbia University, MA, 1983
Columbia College of Physicians and Surgeons, MD, 1987

SPECIALTY: General infectious diseases, HIV primary care, travel medicine

RESEARCH SUMMARY: With a background in cell biology and basic science research, Dr. Flood focuses on clinical infectious diseases. Her interests include general infectious diseases with a particular interest in HIV primary care, infections in immunocompromised patients, endocarditis and septic arthritis. Dr. Flood is also qualified to do travel recommendations and immunizations.

SELECTED PUBLICATIONS:
Furuya, EY, Paez A, Srinivasin A, et al "Outbreak of Mycobacterium abscesses wound infections among "liptourists" from the United States who underwent abdominoplasty in the Domincan Republic". Clin Inf Dis 46(2008):1181-1188.

Flood MT. "Infectious Arthritis." In: Current Practice of Medicine. RC Bone MD ed. Current Medicine, Philadelphia 1996, VIII: 16.1-10.

Brunswick AF, Messeri PA, Dobkin J, Flood MT, Yang A. "Sibling homophily in HIV infection: biopsychosocial linkages in an urban African-American sample. NIDA Research Monograph 151, 1995

Blaner WS, Das Sr, Gouras P, Flood MT. "Hydrolysis of 11-cis and all-trans retinyl palmitate by homogenates of human retinal epithelial cells. J Biol Chem 262 (1987): 53-58.

Flood MT, Gouras P, Kjeldbye H. "Growth characteristics and ultrastructure of human retinal pigment epithelium in vitro. Invest Ophthal Vis Sci 19 (1980): 1309-1320.

OFFICE INFORMATION:
NewYork–Presbyterian Hospital
161 Fort Washington Avenue
Irving Pavilion, Room 215
New York, NY 10032
Tel: 212-305-8039
Fax: 212-305-1754
E-mail: mtf2@columbia.edu

 
 

E. Yoko Furuya, MD

NAME: E. Yoko Furuya, MD, MS

ACADEMIC TITLE:
Assistant Professor of Clinical Medicine

EDUCATION:
Harvard University, BA, 1995
University of Pennsylvania School of Medicine, MD, 1999Columbia University Mailman School of Public Health, MS (Epidemiology), 2006

SPECIALTY: Clinical research in hospital epidemiology and antimicrobial resistance

RESEARCH SUMMARY:
Dr. E. Yoko Furuya is the Medical Director of Infection Prevention & Control and Hospital Epidemiology for all campuses of NewYork-Presbyterian Hospital (Columbia and Cornell). She is also the Director of Antimicrobial Stewardship for NewYork-Presbyterian Hospital (Columbia and Cornell). Her research interests are focused in the areas of hospital epidemiology and antimicrobial resistance. She is a co-investigator on numerous NIH- and CDC-funded grants on topics such as multidrug-resistant gram-negative bacilli, the financial costs of healthcare-associated infections and antimicrobial resistance, the use of electronic data and information technology in hospital epidemiology, and the impact of antimicrobial stewardship, environmental cleaning, and education on rates of multidrug-resistant organisms and Clostridium difficile.  She is also currently working on the evaluation of antimicrobial stewardship interventions on antimicrobial utilization and resistance patterns, as well as the evaluation of a hand hygiene compliance program on the transmission of multidrug-resistant organisms.

SELECTED PUBLICATIONS:
Bernstein DA, Salsgiver E, Simon MS, Greendyke W, Eiras DP, Ito M, Caruso DA, Woodward TM, Perriel OT, Saiman L, Furuya EY, Calfee DP. Understanding Barriers to Optimal Cleaning and Disinfection in Hospitals: A Knowledge, Attitudes, and Practices Survey of Environmental Services Workers. Infect Control Hosp Epidemiol. 2016 Sep 13:1-4. [Epub ahead of print]

Gomez-Simmonds A, Nelson B, Eiras DP, Loo A, Jenkins SG, Whittier S, Calfee DP, Satlin MJ, Kubin CJ, Furuya EY. Combination Regimens for Treatmetn of Carbapenem-Resistant Klebsiella pneumoniae Bloostream Infections. Antimicrob Agents Chemother. 2016 May 23;60(6):3601-7. doi: 10.1128/AAC.03007-15. Print 2016 Jun.

Furuya EY, Dick AW, Herzig CT, Pogorzelska-Maziarz M, Larson EL, Stone PW. Central Line-Associated Bloodstream Infection Reduction and Bundle Compliance in Intensive Care Units: A National Study. Infect Control Hosp Epidemiol. 2016 Jul;37(7):805-10. doi: 10.1017/ice.2016.67. Epub 2016 Apr 7

Edwards JD, Herzig CT, Liu H, Pogorzelska-Maziarz M, Zachariah P, Dick AW, Saiman L, Stone PW, Furuya EY: Central line-associated blood stream infections in pediatric ICUs: Longitudinal trends and compliance with bundle strategies. Am J Infect Control 2015; 43: 489-93.

Vora NM, Kubin CK, Furuya EY: Appropriateness of gram-negative agent use at a tertiary care hospital in the setting of significant antimicrobial resistance. Open Forum Infect Dis 2015. doi: 10.1093/ofid/ofv009

Pogorzelska-Maziarz M, Herzig CT, Larson EL, Furuya EY, Perencevich EN, Stone PW: Implementation of antimicrobial stewardship policies in US hospitals: findings from a national survey. Infect Control Hosp Epidemiol 2015; 36: 261-4.

Nelson BC, Eiras DP, Gomez-Simmonds A, Loo AS, Satlin MJ, Jenkins SG, Whittier S, Calfee DP, Furuya EY, Kubin CJ. Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods. Antimicrob Agents Chemother. 2015 Nov;59(11):7000-6. doi: 10.1128/AAC.00844-15. Epub 2015 Aug 31

Zachariah P, Furuya EY, Edwards J, Dick A, Liu H, Herzig CT, Pogorzelska-Maziarz M, Stone PW, Saiman L: Compliance with prevention practices and their association with central line-associated bloodstream infections in neonatal intensive care units. Am J Infect Control 2014; 42: 847-851.

Patel SJ, Oliveira AP, Zhou JJ, Alba L, Furuya EY, Weisenberg SA, Jia H, Clock SA, Kubin CJ, Jenkins SG, Schuetz AN, Behta M, Della-Latta P, Whittier S, Rhee K, Saiman L: Risk factors and outcomes of infections caused by extremely drug-resistant gram-negative bacilli in patients hospitalized in intensive care units. Am J Infect Control 2014; 42: 626-631.

Stone PW, Pogorzelska-Maziarz M, Herzig CT, Weiner LM, Furuya EY, Dick A, Larson E: State of infection prevention in US hospitals enrolled in the National Health and Safety Network. Am J Infect Control 2014; 42: 94-99.

Gomez-Simmonds A, Kubin CJ, Furuya EY: Comparison of three severity criteria for Clostridium difficile infection. Infect Control Hosp Epidemiol 2014; 35: 196-199.

Bhadelia N, Sonti R, Wright-McCarthy J, Vorenkamp J, Jia H, Saiman L, Furuya EY: Impact of the 2009 influenza A (H1N1) pandemic on healthcare workers at a tertiary care center in New York City. Infect Control Hosp Epidemiol 2013; 34: 825-831.

Zhou JJ, Patel SJ, Jia H, Weisenberg SA, Furuya EY, Kubin CJ, Alba L, Rhee K, Saiman L: Clinicians’ Knowledge, Attitudes, and Practices regarding infections with multidrug-resistant gram-negative bacilli in intensive care units. Infect Control Hosp Epidemiol 34: 274-83, 2013.

Kubin CJ, Jia H, Alba LR, Furuya EY: Lack of significant variability among different methods for calculating antimicrobial days of therapy. Infect Control Hosp Epidemiol 33 (Special Topic Issue: Antimicrobial Stewardship): 421-3, 2012.

Bright TJ, Furuya EY, Kuperman GJ, Cimino JJ, Bakken S: Development and evaluation of an ontology for guiding appropriate antibiotic prescribing. J Biomed Inform 45: 120-8, 2012.

Apte M, Neidell M, Furuya EY, Caplan D, Glied S, Larson E: Using electronically available inpatient hospital data for research. Clin Trans Sci 4: 338-45, 2011.

Pogorzelska M, Stone PW, Furuya EY, Perencevich EN, Goldmann D, Dick A: Impact of the ventilator bundle on ventilator associated pneumonia in intensive care units. Int J Qual Health Care 23: 538-44, 2011.

Furuya EY, Larson E, Landers T, Jia H, Ross B, Behta M: Challenges of applying the SHEA/HICPAC metrics for multidrug-resistant organisms to a real-world setting. Infect Control Hosp Epidemiol 32: 323-32, 2011.

Furuya EY, Dick A, Perencevich EN, Pogorzelska M, Goldmann D, Stone PW: Central line bundle implementation in US intensive care units and impact on bloodstream infections. PLoS One 6:e15452, 2011.

Nguyen M, Eschenauer GA, Bryan M, O'Neil K, Furuya EY, Della-Latta P, Kubin CJ: Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis 67: 180-4, 2010.

Miller M, Cook HA, Furuya EY, Bhat M, Lee MH, Vavagiakis P, Visintainer P, Vasquez G, Larson E, Lowy FD: Staphylococcus aureus in the community: colonization versus infection. PLoS One: 4: e6708, 2009.

Stone PW, Dick A, Pogorzelska M, Horan TC, Furuya EY, Larson E: Staffing and structure of infection prevention and control programs. Am J Infect Control 37: 351-7, 2009.

Furuya EY, Paez A, Srinivasan A, Cooksey R, Augenbraun M, Baron M, Brudney K, Della-Latta P, Estivariz C, Fischer S, Flood M, Kellner P, Roman C, Yakrus M, Weiss D, Granowitz EV: Outbreak of Mycobacterium abscessus wound infections in US lipotourists who underwent abdominoplasty in the Dominican Republic. Clin Infect Dis 46: 1181-8, 2008.

Furuya EY, Cook HA, Lee M, Miller M, Larson E, Hyman S, Della-Latta P, Mendonca E, Lowy FD: Community-associated methicillin-resistant Staphylococcus aureus prevalence: how common is it? A methodological comparison of prevalence ascertainment. Am J Infect Control 35: 359-66, 2007.

Cook H, Furuya EY, Larson E, Vasquez G, Lowy FD: Heterosexual transmission of community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 44: 410-3, 2007.

Furuya EY, Lowy FD: Antimicrobial-resistant bacteria in the community setting. Nature Rev Microbio 4: 36-45, 2006.

Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ: Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemotherapy 54: 566-9, 2004.

Furuya EY, Lowy FD: Antimicrobial strategies for the prevention and treatment of cardiovascular infections including cardiothoracic surgery and device implants. Curr Opin Pharmacol 3: 464-9, 2003.

OFFICE INFORMATION:
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Tel: (212) 305-7185
Fax: (212) 305-7290
E-mail: eyf2002@columbia.edu

 

Back to Top

 
   
 

NAME: Peter Gordon, MD

ACADEMIC TITLE:
Assistant Professor of Clinical Medicine

EDUCATION:
SUNY at Stony Brook, BS, 1986
SUNY at Stony Brook, School of Medicine, MD, 1990

SPECIALTY: HIV primary care, HIV/HCV co-infection, HIV clinical trials.

RESEARCH SUMMARY: Dr. Gordon is the Medical Director of the Comprehensive HIV Program at New York Presbyterian Hospital. His clinical work includes practicing as an HIV Specialist and Primary Care Provider within the Designated AIDS Center at the Columbia University Medical Center and as a clinical investigator within the Columbia Collaborative HIV/AIDS Clinical Trials Unit. Dr. Gordon serves as Chair of the New York State AIDS Institute Quality of Care Advisory Committee, as a member of the AIDS Institute’s Medical Care Criteria Committee, and on the Clinical Committee of Healthix, a regional health information exchange (RHIO) based in NYC.

Dr. Gordon is a co-investigator for the Adult AIDS Clinical Trials Unit at CUMC and a co-investigator for industry-sponsored studies of new antiretroviral agents. He is the principle investigator for a number of HRSA Special Projects of National Significance (SPNS) that focus upon the use of Health Information Technology (HIT) to improve clinical care and care coordination. Additional areas of interest include the use of innovative HIT models for  HIV and STI prevention and care engagement, the impact of chronic HIV on co-morbidities, and HIV health care policy.

SELECTED PUBLICATIONS:
Ramos SR, Gordon P, Bakken S, Schnall R. Sociotechnical Analysis of Health Information Exchange Consent Processes in an HIV Clinic. J Assoc Nurses AIDS Care. 2016 Aug 16. pii: S1055-3290(16)30108-X. doi: 10.1016/j.jana.2016.08.001. [Epub ahead of print]

Lekas HM, Alfandre D, Gordon P, Harwood K, Yin MT. The role of patient-provider interactions: Using an accounts framework to explain hospital discharges against medical advice. Soc Sci Med. 2016 May;156:106-13. doi: 10.1016/j.socscimed.2016.03.018. Epub 2016 Mar 15.

Feller DJ, Akiyama MJ, Gordon P, Agins BD. Readmissions in HIV-Infected Inpatients: A Large Cohort Analysis. J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):407-12. doi: 10.1097/QAI.0000000000000876.

O'Neill M, Karelas GD, Feller DJ, Knudsen-Strong E, Lajeunesse D, Tsui D, Gordon P, Agins BD. The HIV Workforce in New York State: Does Patient Volume Correlate with Quality? Clin Infect Dis. 2015 Dec 15;61(12):1871-7. doi: 10.1093/cid/civ719. Epub 2015 Sep 30.

Odlum M, Gordon P, Camhi E, Valdez E, Bakken S. Exploring factors related to the adoption and acceptance of an internet-based electronic personal health management tool (EPHMT) in a low income, special needs population of people living with HIV and AIDS in New York City. Stud Health Technol Inform. 2014;201:145-52.

Odlum M, Gordon P, Camhi E, Schnall R, Teixeira P, Bakken S. Perceptions of Predisposing, Enabling, and Reinforcing Factors for Use of a Continuity of Care Document for People Living with HIV/AIDS, Journal of Healthcare for Poor and Underserved. 2012;23(4):1457-76

Gordon P, Camhi E, Odlum M, Schnall R, Rodriguez M, Valdez E, Bakken S. Processes and Outcomes of Developing a Continuity of Care Document for Use as a Personal Health Record by People Living with HIV/AIDS in New York City. International Journal of Medical Informatics. 2012; 81(10): e63-73

Schnall R, Smith AB, Sikka M, Gordon P, Camhi E, Kanter T, Bakken S. Employing the FITT framework to explore HIV case managers' perceptions of two electronic clinical data (ECD) summary systems. International Journal of Medical Informatics. 2012; 81(10): e56-72

Schnall R, Smith, SB, Gordon P, Camhi E, Sikka M, Kanter T, Bakken S. Barriers and Facilitators of Implementing Personal Health Records in HIV/AIDS Care. Studies in Health Technology and Informatics, 2012

Schnall R, Gordon P, Camhi E, Bakken S. Perceptions of Factors Influencing Use of an Electronic Record for Case Management of Persons Living with HIV. AIDS Care. 2011 Mar;23(3):357-65

Teixeira PA, Gordon P, Canhi E, Bakken S. HIV Patients’ Willingness to Share Personal Health Information Electronically. Patient Education and Counseling. 2011 Aug: 84(2):e9-12

Schnall R, Odlum M, Gordon P, Bakken S. Barriers to implementation of a Continuity of Care Record (CCR) in HIV/ AIDS care. Studies in Health Technology and Informatics 2009;146:248-52

Stetson P, Hripsak G, Gordon P, Using the Federated Council for Internal Medicine curricular guide and administrative codes to assess IM residents' breadth of experience. Academic Medicine 2004; 79(6):557-63

OFFICE INFORMATION:
Harkness Pavilion, 6th Floor
180 Fort Washington Avenue
New York, NY 10032
Tel: 212-305-3272
Fax: 212-305-7692
E-mail: pgg2@columbia.edu

 

Back to Top

 

NAME: Rachel J. Gordon, MD, MPH

ACADEMIC TITLE:
Assistant Professor of Clinical Medicine
Assistant Professor of Clinical Epidemiology


EDUCATION:
Yale University, B.S., 1996
Vanderbilt University School of Medicine, M.D., 2000
Columbia University Mailman School of Public Health, M.P.H. 2004

SPECIALTY: Staphylococcal molecular epidemiology and pathogenesis


RESEARCH SUMMARY: Dr. Rachel Gordon is an Assistant Professor in Clinical Medicine in the Division of Infectious Diseases at the Columbia University Medical Center and in epidemiology at the Mailman School of Public Health. Her research interests include the molecular epidemiology of Staphylococcal colonization and disease in high-risk populations as well as Staphylococcal pathogenesis. Dr. Gordon has been investigating ventricular assist device-related infections (VADs) and the molecular epidemiology of Staphylococcus epidermidis, which is frequently involved with these infections. She is also interested in bacterial infections in drug users.  Dr. Gordon is also an active educator, the recipient of several teaching awards and is a member of the Virginia Apgar Academy of Medical Educators.  She is the section director for Microbiology/Infectious Diseases at Physcians & Surgeons and teaches “Biology and Pathophysiology for Epidemiologist” in the Epidemiology doctoral program at the Mailman School of Public Health.  She enjoys working with and training clinical fellows and residents.

SELECTED PUBLICATIONS:
Gordon, R. J., A. D. Weinberg, F. D. Pagani, M. S. Slaughter, P. S. Pappas, Y. Naka, D. J. Goldstein, W. P. Dembitsky, J. C. Giacalone, J. Ferrante, D. D. Ascheim, A. J. Moskowitz, E. A. Rose, A. C. Gelijns, and F. D. Lowy. 2013. Prospective, multicenter study of ventricular assist device infections. Circulation 127:691-702.  PubMed # 23315371 NIHMSID # 440295

Gordon, Rachel J.,  Maria Miragaia, Alan D. Weinberg, Caroline J Lee, Joana Rolo, Julie C. Giacolone, Mark S. Slaughter, Pat Pappas, Yoshifumi Naka, Alfred J. Tector, Herminia de Lencastre, Franklin D. Lowy.  Staphylococcus epidermidis colonization is  highly clonal across United States cardiac centers.  Journal of Infectious Diseases. 2012 May 1;205(9):1391-8.

Gordon, Rachel J., N. Chez, H. Jia, B. Zeller, M. Sobieszczyk, C. Brennan, K. Hisert, Mei-Ho Lee, P. Vavagiakis, and Franklin D. Lowy. The NOSE Study (Nasal Ointment for Staphylococcus aureus Eradication): A Randomized Controlled Trial of Monthly Mupirocin in HIV-Infected Individuals. J of Acquired Immune Deficiency Syndromes. 2010 Sept;55(2).

Schulman AR, Martens TP, Russo MJ, Christos PJ, Gordon RJ, Lowy FD, Oz MC, Naka Y. Effect of left ventricular assist device infection on post-transplant outcomes. J Heart Lung Transplant. 2009 Mar;28(3):237-42.

Gordon, R.J. and F.D. Lowy. Pathogenesis of Methicillin-Resistant Staphylococcus aureus Infection. Clinical Infectious Diseases 2008; 46:S350-9.

Gordon, R.J., B. Quagliarello, and F.D. Lowy. Ventricular assist device-related infections. Lancet Infect. Dis. 2006; 6:426-37.

Gordon, R.J. and F.D. Lowy. Bacterial Infections in Drug Users. NEJM 2005; 353:1945-54.

Gordon, R.J., B. Quagliarello, C. Cespedes, M. Chung, H. de Lencastre, P. Vavagiakis, M. Miller, B. Zeller, and F.D. Lowy. A Molecular Epidemiological Analysis of 2 Staphylococcus aureus Clonal Types Colonizing and Infecting Patients with AIDS. Clin. Infect. Dis. 2005;40:1028-1036.

Cespedes, C., B. Said-Salim, M. Miller, S.H. Lo, B.N. Kreiswirth, R.J. Gordon, P. Vavagiakis, R.S. Klein, and F.D. Lowy FD. The clonality of Staphylococcus aureus nasal carriage. J. Infect. Dis. 2005;191(3):444-52.

ABSTRACTS

Rachel J. Gordon, MD, MPH, William J. Pluta, Boyd F. Richards, PhD.  Innovative Strategies for Active Learning within a “Flipped” Classroom Environment: Team-based Learning and Just-In-Time Teaching Compared.  Presentation Proposal submitted to the Association of American Medical Colleges’ NEGEA Educational Retreat Spring Meeting April 2013, New York, NY.

N. A. Weitz, F. N. White, R. J. Gordon, K. D. Morel, M. C. Garzon, P. J. Planet, C. T. Lauren.  Staphylococcus aureus Colonization in Children with Atopic Dermatitis. Summer Academy Meeting of the American Academy of Dermatology, Boston, MA August 2012.

R. Gordon, A. Weinberg, F. Pagani, F. Lowy, and the VAD Infection Study Group. Prospective, multicenter investigation of ventricular assist device infections.  Late-breaker, 50th Annual ICAAC Meeting, Boston, September 2010.

R. Gordon, M. Perlo, E. Hall.  Innovative Teaching Methods: The Challenge of Effectively Training Faculty. Poster presentation at the NEGEA Annual Retreat at the University of Connecticut School of Medicine in Farmington, CT, March 2010.

Uhlemann-AC, Huard-R, Whittier-S, Della-Latta-P, Lowy-FD, Gordon-RJ. Clinical Vancomycin-Intermediate S. aureus (VISA) infection with a USA 300 strain. 48th Annual ICAAC/IDSA 46th Annual Meeting, Washington, DC., October 2008.

R. Gordon, N. Chez, H. Jia, B. Zeller, M. Sobieszczyk, C. Brennan, K. Hisert, M. Lee, P. Vavagiakis, F. Lowy. Monthly mupirocin decreases S. aureus nasal colonization in HIV/AIDS patients. Poster presentation at the 48th Annual ICAAC/IDSA 46th Annual Meeting, October 2008.

R. Gordon, M. Bhat, C. Fairchild, J. Choe, U. Rawiel, D. Ascheim, M. Slaughter, Y. Naka, F. Lowy. Ventricular Assist Device Recipients Share Commensal S. epidermidis Clones and are Infected with Colonizing Strains. Poster presentation at the 48th Annual ICAAC/IDSA 46th Annual Meeting, October 2008.

Gordon, R. J., T. Martens, R. Wang, Y. Naka, B. Scully, E. Blumberg, and F. Lowy. Diagnostic Criteria for Diagnosing Ventricular Assist Device-Related Infections. Poster presentation at the 46th ICAAC, September, 2006.

OFFICE INFORMATION:
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Tel: (212) 342-0109
Fax: (212) 305-5794
E-mail: rj216@columbia.edu

 

Back to Top

 
Sandra Hyman

NAME: Sandra Hyman, RN, MPA, CIC

ACADEMIC TITLE:

Associate in Medicine

EDUCATION:
Molloy College, BSN, 1981
New York University, MPA, 1986


SPECIALTY: Infection Prevention and Control, Quality and Safety

RESEARCH SUMMARY: Sandra R. Hyman, RN, MPA,CIC , has been an Infection Prevention, and Safety Specialist at NewYork-Presbyterian Hospital (NYPH) for over 11 years, and is an Associate in Medicine at the Columbia University, Department of Medicine, Division of Infectious Diseases. For the last 6 years at (NYPH) she has been providing education and infection prevention support for the adult and children’s Perioperative Services. She is part of thePerioperative Services Leadership. In addition, Sandra Hyman has been a member of a research team at the Columbia University Center for Interdisciplinary Research to Reduce Antimicrobial Resistance. The team had aNIH Grant to study the economics of hospital infections.

Prior to NYPH she was an Infection Control Coordinator at Greenwich Hospital, in Greenwich, Connecticut (CT) for 15 years. She specialized in community acute care, home care and private office consulting. Sandra also managed some Employee Health functions. Sandra has been a member of The Association for Professionals in Infection Control and Epidemiology (APIC) for nearly 30 years, and served as Vice Chairman for the CTAPIC Conference. She was a recent member of the APIC National Education Committee and the Education Committee liaison for the APIC Professional Development Committee. She was the content expert for the Advanced APIC Surgical Site Infection Prevention Curriculum and has delivered multiple APIC sponsored practices. The new resident infection prevention training program has been shared in multiple webinars. Sandra is on the Advisory Board for the American Journal of Infection Control (AJIC) and has reviewed articlesfor AJIC and the Joint Commission Journal on Quality and Patient Safety.

SELECTED PUBLICATIONS:
Hogle NJ, Cohen B, Hyman S, Larson E, Fowler DL. 2014. Incidence and risk factors for and the effect of a program to reduce the incidence of surgical site infection after cardiac surgery. Surg Infect.15(3): 299-304

Cohen B, Choi YJ, Hyman S, Furuya EY, Neidell M, Larson E. 2013. Gender differences in risk of bloodstream and surgical site infections. J Gen Intern Med. 28(10): 1318-25.

S. Hyman, RN, MPA, S. Shim, RN, BSN, L. Kertesz, ANP, MSN , N. Nadera, RN, MSN, R. Alexander, RN, BSN, M. Wilheim, ORT, C. Polak-Reid, RN, Improving Communication and Compliance: Role of a Perioperative Infection Prevention Committee, Association for Infection Prevention and Epidemiology, Fort Lauderdale, Florida, May 2013

S. Hyman, RN, MPA, CIC, L. Kertesz, ANP, MSN, CNOR, P. Nelson, RN, MSN,P. Nelson, RN, MSN, CNOR, A. Compton, MD, MPH, V. Almarez-Fox, RN, MPA, J. Evanko, MD, MBA, Engaging Staff to be Responsible for Surgical Site Infection Prevention in a Large Academic Tertiary Hospital, Association for Professionals in Infection Control and Epidemiology, San Antonio, Texas, June 2012

Cohen B, Choi YJ, Hyman, SR, Furuya, EY, Neidell M, Larson, EL, Gender Differences in Risk of Bloodstream Infection, Journal of General Internal Medicine, 28(4) and Association for Professionals in Infection Control and Epidemiology, San Antonio, Texas, April 2013

S. Hyman, RN, MPA, CIC, K. Gasiorowski, RN, MSN, CNOR, L.Kertesz, ANP, MSN, CNOR, L. Posner, RN, BSN, M. O’Brien, RN, MA, CNOR SCIP-ing to the Next Level: Surgical Site Infection Prevention, Association of periOperative Registered Nurses, New Orleans, Louisiana, March 2012

M. Apte,MS, T. Landers, RN, Ph.D., E. Furuya, MD, MS, S. Hyman, RN, MPA,E. Larson, RN, PhD, A Comparison of Two Computer Algorithms to Identify Surgical Site Infections, Journal of Surgical Infections 2011 Dec;12(6):459-64 and Association for Infection Prevention, New Orleans, Louisiana, Oct 2011

S. Hyman, RN, MPA, CIC, B. Cohen, MPH, L. Rosenberg, BS, E. Larson, RN, Ph.D., Frequency, Level, and Duration of Patient Contacts, And Observational Study and Survey of Physicians, Nurses, Clinical Staff and Visitors, Association for Infection Prevention, Baltimore, Maryland, New York Academy of Medicine, Nursing Research Seminar, and The Joint Commission Journal of Quality and Patient Safety, Oct. and June 2012

T. Landers, CNP, Ph.D., M. Apte, MBBS, MsPH, S.Hyman, RN,MPA,CIC, E. Y. Furuya, MD, S. Glied, PhD, E. Larson, RN, PhD, A Comparison of Methods to Detect Urinary Tract Infections Using Electronic Data, The Joint Commission Journal of Quality and Patient Safety, September 2010

S. Hyman, RN, MPA, CIC, P. Bernstein, BSN, RN, CIC, S. Shim, RN, BSN, CNOR., M. Messina, RN, BSN, P. Angevine, MD, MPH, et.al. A Multidisciplinary Approach to Surgical Site Infection Reduction, Association for Infection Prevention, New Orleans, Louisiana , July 2010

Carey AJ, Graham PL, Hyman S, Carp D, Wu F, Della-Latta P, Rubenstein D, Saiman L. Molecular epidemiology of methicillin resistant Staphylococcus aureus in a level III-IV neonatal intensive care unit. Society of Pediatric Research, San Francisco, CA , April 2006

Hyman S, Wajngurt D, Hwang E, Furuya EY, Hong F, Fracaro M, Hammer S, Shortliffe E et al. Model for Designing Advanced Technological Tools to Enhance Infection Control Surveillance. Society for Healthcare Epidemiologists of America Oct 2005

Sabetta, JR, MD, Hyman, SR, MPA,CIC, Smardin, J., CIC, Foodborne Nosocomial Outbreak of Salmonella reading - Connecticut MMWR, and JAMA, December 25,1991

 

OFFICE INFORMATION:

177 Fort Washington Avenue

Milstein 3GN Room 432

New York, NY 10032

Tel: 212-305-4611

Fax: 212-305-8292

 

Back to Top

 

Justman

NAME: Jessica Justman, MD

ACADEMIC TITLE:
Associate Professor of Medicine in Epidemiology at CUMC

EDUCATION:
Yale University, BS, 1981
University of Rochester, MD, 1985

SPECIALTY: HIV epidemiology, HIV prevention clinical research,  metabolic complications of antiretroviral therapy


RESEARCH SUMMARY:
Dr. Justman’s research interests focus on HIV prevention, with a focus on microbicides and other aspects of HIV in women, international HIV epidemiology and combination HIV prevention studies, as well as the metabolic complications of HIV. She established and continues to lead the Bronx-Lebanon HIV prevention clinical research site which conducts NIH-funded HIV Prevention Trials Network (HPTN) and Microbicide Trials Network (MTN) studies, such as HPTN 064, the Women’s HIV Seroincidence Study, and MTN 014, a pharmacokinetic study of vaginal versus rectal use of reduced-glycerin tenofovir gel.   Dr. Justman is also a principal investigator of three international studies: the Swaziland HIV Incidence Measurement Survey, an observational study of a household-based, nationally representative cohort to assess the national impact of male circumcision and other HIV prevention programs in Swaziland; and two assessments of district-wide combination HIV prevention programs, one in Sinazongwe, Zambia and one in Bukoba, Tanzania. 

At the Mailman School of Public Health (MSPH), as Senior Technical Director at ICAP, she oversees technical assistance for the clinical and strategic information activities needed for HIV programs and health systems strengthening. From 2008 to 2010, Dr. Justman chaired the New York State Department of Health AIDS Institute’s committee on clinical guidelines for adults with HIV.

SELECTED PUBLICATIONS:
Bock NN, Emerson RC, Reed JB, Nkambule R, Donnell DJ, Bicego GT, Okello V, Philip NM, Ehrenkranz PD, Duong YT, Moore JS, Justman JE. Changing Antiretroviral Eligibility Criteria: Impact on the Number and Proportion of Adults Requiring Treatment in Swaziland. J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):338-44.

McNairy ML, Gwynn C, Rabkin M, Antelman G, Wu Y, Alemayehu B, Lim T, Imtiaz R, Mosha F, Mwasekaga M, Othman AA, Justman J. Increased utilisation of PEPFAR-supported laboratory services by non-HIV patents in Tanzania. Afr J Lab Med. 2016;5(1). pii: 318. Epub 2016 Feb 16.

McNairy ML, Lamb MR, Abrams EJ, Elul B, Sahabo R, Hawken MP, Mussa A, Zwede A, Justman J, El-Sadr WM. Use of a Comprehensive HIV Care Cascade for Evaluating HIV Program Performance: Findings From 4 Sub-Saharan African Countries. Identifying Optimal Models of HIV Care and Treatment in Sub-Saharan Africa Study. J Acquir Immune Defic Syndr. 2015 Oct 1;70(2):e44-51.

Justman J, Befus M, Hughes J, Wang J, Golin CE, Adimora AA, Kuo I, Haley DF, Del Rio C, El-Sadr WM, Rompalo A, Mannheimer S, Soto-Torres L, Hodder S. Sexual Behaviors of US Women at Risk of HIV Acquisition: A Longitudinal Analysis of Findings from HPTN 064. AIDS Behav. 2015 Jul;19(7):1327-37.

El-Sadr WM, Philip NM, Justman J. Letting HIV transform academia-embracing implementation science. N Engl J Med. 2014 May 1;370(18):1679-81. doi: 10.1056/NEJMp1314777.

C.W. Hendrix, B.A.Chen, V. Guddera, C. Hoesley, J. Justman, C. Nakabiito, R. Salata, L. Soto-Torres, K. Patterson, A.M. Minnis, S.Gandham, K. Gomez, J. Schwartz, B.A. Richardson, N. Bumpus. MTN-001: Pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One 20138(1):e55013.

S.L. Hodder, J.Justman, J. Hughes , J. Wang, D.F. Haley, A.A. Adimora, C.Del Rio, C.E. Golin, I. Kuo, A. Rompalo, L. Soto-Torres, S.B. Mannheimer, L. Johnson-Lewis, S.H. Eshleman, W.M. El-Sadr. HIV Acquisition Among Women from Selected Areas of the United States. Ann Intern Med. 2013 158:10-18.

S.H. Eshleman, J.P. Hughes, O. Laeyendecker, J. Wang, R. Brookmeyer, L. Johnson-Lewis, C.E. Mullis, J. Hackett, A.S. Vallari, J. Justman, S.L. Hodder. Use of a multi-faceted approach to assess HIV incidence in a cohort study of women in the United States: HIV Prevention Trials Network 064 Study. J Infect Dis. 2013. 207:223-31.

Chin CD, Laksanasopin T, Cheung YK, Steinmiller D, Linder V, Parsa H, Wang J, Moore H, Rouse R, Umviligihozo G, Karita E, Mwambarangwe L, Braunstein SL, van de Wijgert J, Sahabo R, Justman JE, El-Sadr W, Sia SK. Microfluidics-base diagnostics of infectious diseases in the developing world. Nat Med. 2011. 17:1015-9.

Hodder SL, Justman J, Haley DF, Adimora AA, Fogel CI, Golin CE, O'Leary A,Soto-Torres L, Wingood G, El-Sadr WM; HIV Prevention Trials Network Domestic Prevention in Women Working Group. Challenges of a hidden epidemic: HIV prevention among women in the United States. J Acquir Immune Defic Syndr. 2010. 55 Suppl 2:S69-73.

B. Cutler, J. Justman. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis. 2008. 11:685-97.

M.E. Sobieszczyk, D.R. Hoover, K. Anastos, K. Mulligan, T. Tan, Q. Shi, W. Gao, C. Hyman, M.H. Cohen, SR. Cole, M.W. Plankey, A.M. Levine, J. Justman. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women’s Interagency HIV Study. J Acquir Immune Defic Syndr. 2008 48:272-80.

J.E. Justman, D.R. Hoover, Q. Shi , T. Tan, K. Anastos, P.C. Tien ,S.R. Cole, C. Hyman , R. Karim, K. Weber, S. Grinspoon. Longitudinal anthropometric patterns among HIV-infected and uninfected women. JAIDS. 2008. 47: 312-9.

K.H. Mayer, L.A.Maslankowski, F. Gai, W.M. El-Sadr, J. Justman, A. Kwiecien, B. Masse, S.H. Eshleman, C. Hendrix, K. Morrow, J.F. Rooney, L. Soto-Torres. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006. 20:543-51.

J.E. Justman, L. Benning, A. Danoff, H. Minkoff, A. Levine, R.M. Greenblatt, K. Weber, E. Piessens, E. Robinson, K. Anastos. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003. 32:298-302.

OFFICE INFORMATION:
722 W 168th Street, Room 1315
Columbia University Medical Center
New York, New York 10032
Tel: 212-342-0537
E-mail: jj2158@columbia.edu

 

Back to Top

 

knirsch image

NAME: Charles Knirsch, MD, MPH

ACADEMIC TITLE:
Adjunct Assistant Professor of Medicine

EDUCATION:
McGill University, BSc, 1981
McGill University, MD, 1985
Columbia University, MPH, 1995

SPECIALTY: TB, travel medicine

RESEARCH SUMMARY:

Charles Knirsch, MD, MPH research has integrated work with several Public-Private-Partnerships to collaborate on disease control and elimination programs. This has involved work on addressing information management for tuberculosis patient treatment protocols and hospital epidemiology in New York to more recent international sector collaborations on malaria with The National Institutes of Health and The Centers for Disease Control and Prevention. Chuck currently collaborates with The World Health Organization and The International Trachoma Initiative on a program to eliminate blinding trachoma by the year 2020.

SELECTED PUBLICATIONS:
Alemayehu D, Quinn J, Cook J, Kunkel M, Knirsch CA. A paradigm shift in drug development for treatment of rare multidrug-resistant gram-negative pathogens. Clin Infect Dis. 2012 Aug; 55(4):562-7

Alemayehu D, Andrews EN, Glue P, Knirsch CA. Considerations for the design and conduct of a pharmacovigilance study involving mass drug administration in a resource-constrained setting. PLoS Negl Trop Dis. 2010 Jan 26; 4(1):e564

Knirsch CA, Chandra R. Azithromycin and the risk of cardiovascular death. N ENgl J Med. 2012 Aug 23; 367(8):772-3; author reply 775.

El-Tahtawy A, Glue P, Andrews EN, Mardekian J, Amsden GW, Knirsch CA. The Effect of Azithromycin on Ivermectin Pharmacokinetics – A Population Pharmacokinetic Model Analysis. PLoS Negl Trop Dis. 2008 May 14;2(5):e236.

Knirsch C. Trachoma: ancient scourge, disease elimination, and future research.
Curr Infect Dis Rep. 2007 Jan;9(1):21-8.

Noedl H, Krudsood S, Leowattana W, Tangpukdee N, Thanachartwet W, Looareesuwan S, Miller RS, Fukuda M, Jongsakul K, Yingyuen K, Sriwichai S, Ohrt C, Knirsch C. In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. Antimicrob Agents Chemother. 2007 Feb;51(2):651-6.

Noedl H, Krudsood S, Chalermratana K, Silachamroon U, Leowattana W, Tangpukdee N, Looareesuwan S, Miller RS, Fukuda M, Jongsakul K, Sriwichai S, Rowan J, Bhattacharyya H, Ohrt C, Knirsch C. Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodium falciparum malaria in adults: a randomized, phase 2 clinical trial in Thailand. Clin Infect Dis. 2006 Nov 15;43(10):1264-71.

Mecaskey JW, Knirsch CA, Kumaresan JA, Cook JA. The possibility of eliminating blinding trachoma. Lancet Infect Dis. 2003 Nov;3(11):728-34.

Barr RG, Diez-Roux AV, Knirsch CA, Pablos-Méndez A. Neighborhood poverty and the resurgence of Tuberculosis in New York City, 1984 to 1992. Am J Public Health 2001 Sep;91(9):1487-93.

Hripcsak G, Knirsch CA, Jain N, Stazesky RC, Pablos-Mendez A, Fulmer T. A health information network for managing inner-city Tuberculosis: Bridging clinical care, public health, and home care. Computers and Biomedical Research 1999 Feb;32 (1):67-76.

Knirsch CA, Jain NL, Pablos-Mendez A, Friedman C, Hripcsak G.  Tuberculosis Detection and Moni­toring by an Automated Clinical Decision Support System. Infect Control Hosp Epidemiol 1998;19 (2) 94-100.

Pablos-Mendez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 1997; 87:574-579.

Pablos-Mendez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Noncompliance with antituberculosis treatment: Predictors and consequences in New York City. Am J Med 1997;102:164-170.

OFFICE INFORMATION:
Pfizer Inc.
235 East 42nd Street
New York, NY 10017

 

Back to Top

 

Christine J. Kubin, PharmD, BCPS

http://www.cumc.columbia.edu/dept/id/images/spacer.gif

NAME: Christine J. Kubin, PharmD, BCPS (AQ-ID)

ACADEMIC TITLE:
Assistant in Medicine

EDUCATION:
University of North Carolina at Chapel Hill, PharmD, 1998

SPECIALTY: Anti-infective pharmacology and therapeutics, antimicrobial resistance and epidemiology

RESEARCH SUMMARY: Dr. Kubin is the Clinical Pharmacy Manager in the Division of Infectious Diseases at NewYork–Presbyterian Hospital, Columbia University Medical Center and a board-certified pharmacotherapy specialist with added qualifications in infectious diseases. Her research interests focus on anti-infective treatment outcomes and the epidemiology of multi-drug resistant pathogens. Dr. Kubin is a member of the joint Anti-Infective Subcommittee at NewYork–Presbyterian Hospital and co-spearheads antimicrobial stewardship activities with Dr. Furuya. Current projects include evaluating treatment outcomes and therapies for infections caused by carbapenem-resistant organisms with a specific focus on optimal polymyxin B regimens and dosing. She is also currently working on projects related to outcomes in immunosuppressed populations, patients with Clostridium difficile infection, evaluating the relationships of antibiotic utilization and resistance within the hospital, and surgical site infections.


SELECTED PUBLICATIONS:
Pouch SM, Kubin CJ, Satlin MJ, Tsapepas DS, Lee JR, Dube G, Pereira MR. Epidemiology and outcomes of carbapenem-resistant Klebsiella pneumoniae bacteriuria in kidney transplant recipients. Transpl Infect Dis. 2015 Dec;17(6):800-9. doi: 10.1111/tid.12450. Epub 2015 Nov

Nelson BC, Eiras DP, Gomez-Simmonds A, Loo AS, Satlin MJ, Jenkins SG, Whittier S, Calfee DP, Furuya EY, Kubin CJ. Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods. Antimicrob Agents Chemother. 2015 Nov;59(11):7000-6. doi: 10.1128/AAC.00844-15. Epub 2015 Aug 31.

Vora NM, Kubin CJ, Furuya EY. Appropriateness of gram-negative agent use at a tertiary care hospital in the setting of significant antimicrobial resistance. Open Forum Infect Dis. 2015 Feb 19;2(1):ofv009. doi: 10.1093/ofid/ofv009. eCollection 2015 Jan.

Gomez-Simmonds A, Kubin CJ, Furuya EY. Comparison of 3 severity criteria for Clostridium difficile infection. Infect Control Hosp Epidemiol 2014; 35(2): 196-9.

Eschenauer GA, Nguyen MH, Shoham S, Vazquez JA, Morris AJ, Pasculle WA, Kubin CJ, Klinker KP, Carver PL, Hanson KE, Chen S, Lam SW, Potoski BA, Clarke LG, Shields RK, Clancy CJ. Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. Antimicrob Agents Chemother 2014; 58(4):1897-906.

Shah SA, Tsapepas DS, Kubin CJ, Martin ST, Mohan S, Ratner LE, Pereira M, Kapur S, Dadhania D, Walker-McDermott JK. Risk factors associated with Clostridium difficile infection after kidney and pancreas transplantation. Transpl Infect Dis 2013; 15(5):502-9.

Kubin CJ, Jia H, Alba LR, Furuya EY. Lack of significant variability among different methods for calculating antimicrobial days of therapy. Infect Control Hosp Epidemiol 2012; 33 (Special Topic Issue: Antimicrobial Stewardship):421-3.

Thomas TA, Broun EC, Abildskov KM, Kubin CJ, Horan J, Yin MT, Cremers S. High performance liquid chromatography-mass spectrometry assay for polymyxin B1 and B2 in human plasma. Ther Drug Monit 2012; 34(4):398-405.

Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MT. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 2012; 65(1):80-7.

Nguyen M, Eschenauer GA, Bryan M, O'Neil K, Furuya EY, Della-Latta P, Kubin CJ Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis. 2010 Jun;67(2):180-4. doi: 10.1016/j.diagmicrobio.2010.02.001. Epub 2010 Mar 31.

Satlin MJ, Kubin CJ, Blumenthal JS, Cohen AB, Furuya EY, Wilson SJ, Jenkins SG, Calfee DP. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 2011; 55(12):5893-9.

Lat A, Clock SA, Wu F, Whittier S, Della-Latta P, Fauntleroy K, Jenkins SG, Saiman L, Kubin CJ. Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest. J Clin Microbiol 2011; 49(5):1795-8.

Kubin CJ. Antimicrobial stewardship programs: role in optimizing infectious disease outcomes. Disease Management and Health Outcomes 2008; 16(6):403-410.

Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ. Combination therapy with polymyxin B for the treatment of multidrug-resistant gram-negative respiratory tract infections. Journal of Antimicrobial Chemotherapy 2004; 54(2):566-9.

OFFICE INFORMATION:
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Tel: 212-305-7185
Fax: 212-305-7290
E-mail: cck27@columbia.edu

 

 

 

Back to Top

 

Franklin Lowy, MD

http://cait.columbia.edu:88/dept/id/images/spacer.gif

NAME: Franklin Lowy, MD

ACADEMIC TITLE:
Professor of Medicine and Pathology

EDUCATION:
Columbia College BA, 1968
Columbia University College of Physicians and Surgeons, MD, 1972

SPECIALTY: Internal Medicine and Infectious Diseases

RESEARCH SUMMARY: Dr. Franklin Lowy’s laboratory investigates the pathogenesis and epidemiology of Staphylococcus aureus and Staphylococcus epidermidis infections.

Studies on the pathogenesis of staphylococcal infections: Recent projects have focused on the role of different S. aureus and S. epidermidis surface proteins as mediators of adherence to prosthetic devices such as left ventricular assist devices. The goal of these studies has been to characterize the role of these proteins in the initiation of device-related infections. A second series of studies investigates the treatment and pathogenesis of S. aureus osteomyelitis using a murine model.

Studies on the transmission of S. aureus among high-risk populations: A household-based study investigated how community-associated methicillin-resistant S. aureus (CA-MRSA) is spread in the predominantly Dominican population that surrounds Columbia University Medical Center. Genetic characterization of these isolates as they spread within the community examined whether adaptive changes facilitate spread. The goal of these studies was to understand the factors that contribute to the transmission of S. aureus within this population. A second component of this investigation was to examine the spread of a unique methicillin-susceptible S. aureus, strain ST398. This clone, a common cause of infections among farmers in the Netherlands, is prevalent in Northern Manhattan and is responsible for an increasing number of clinical infections.

A different transmission study examined how CA-MRSA strains are introduced into and spread within the NYS prison system. The study examined the clonal nature of infections in the prison system, their source and the impact of inmate movement on the dissemination of these unique clones of S. aureus. Molecular epidemiologic techniques were used to characterize the predominant isolates in the two facilities. The role of inmate transfer on the spread of these epidemic strains was also examined.

A new project is using a genomic approach to map the distribution of antimicrobial resistance genes in different New York City neighborhoods. The ultimate goal is to create a New York City map of the distribution of antibiotic resistance genes and then use this to identify risks that contribute to high resistance levels in different geographic areas of the city.

SELECTED PUBLICATIONS:
Lowy, F.D. Staphylococcal Infections In: Harrison’s Principles of Internal Medicine, 20th edition.  Editors: D. L. Longo, A. S. Fauci, D.L. Kasper, S. L. Hauser, J. L. Jameson andJ.Loscalzo. The McGraw- Hill Companies, Inc., In Press 2017.

Befus MB, Miko BA, Herzig CT, Keleekai N, Mukherjee DV, Larson E, Lowy F.D. HIV and colonization with Staphylococcus aureus in two maximum-security prisons in New York State. J Infect. 2016 Sep 1. pii: S0163-4453(16)30220-1. doi: 10.1016/j.jinf.2016.08.016. [Epub ahead of print]

Knox J, Sullivan SB, Urena J, Miller M, Vavagiakis P, Shi Q, Uhlemann AC, Lowy F.D.Association of Environmental Contamination in the Home With the Risk for Recurrent Community-Associated, Methicillin-Resistant Staphylococcus aureus Infection. JAMA Intern Med. 2016 Jun 1;176(6):807-15. doi: 10.1001/jamainternmed.2016.1500.

Knox, J., Uhlemann, A.C. and Lowy, F.D. Transmission of Staphylococcus aureus within households and community. Trends Microbiol, Invited perspective, 20:1-8, 2015. doi: 10.1016/j.tim.2015.03.007. Epub 2015 Apr 9. Review.

Miko BA, Befus M, Herzig CT, Mukherjee DV, Apa ZL, Bai RY, Tanner JP, Gage D, Genovese M, Koenigsmann CJ, Larson EL, Lowy F.D. Epidemiological and biological determinants of Staphylococcus aureus clinical infection in New York State maximum security prisons. Clin Infect Dis. 2015 Jul 15;61(2):203-10. doi: 10.1093/cid/civ242. Epub 2015 Mar 25.

Knox J, Van Rijen M, Uhlemann AC, Miller M, Hafer C, Vavagiakis P, Shi Q, Johnson PD, Coombs G, Kluytmans-Van Den Bergh M, Kluytmans J, Bennett CM, Lowy F.D. Community-associated methicillin-resistant Staphylococcus aureus transmission in households of infected cases: a pooled analysis of primary data from three studies across international settings. Epidemiol Infect. 2015 Jan;143(2):354-65. doi:10.1017/S0950268814000983. Epub 2014 Apr 24.

Tanner J, Lin Y, Kornblum J, Herzig CT, Bystritsky R, Uhlemann AC, Lowy F.DMolecular characterization of methicillin-resistant Staphylococcus aureus clinical isolates obtained from the Rikers Island Jail System from 2009 to 2013. J Clin Microbiol. 2014 Aug;52(8):3091-4. doi: 10.1128/JCM.01129-14. Epub 2014 Jun 4.

Uhlemann, A-C, Dordel, J., Knox, J., Raven, K., Parkhill, J., Holden, M.T.G., Peacock, S.J. and Lowy, F.D. Molecular tracing of the emergence, diversification and transmission of S. aureus sequence type 8/USA300 in a New York community. Proc Nat Acad Sci USA 111:4988-93, 2014.

Gordon, R.J., Weinberg, A.D., Pagani F.D., Slaughter, M.S., Pappas, P.S., Naka, Y., Goldstein, D.J., Dembitsky, W.P., Giacalone, J.C., Ferrante, J., Ascheim, D.D., Moskowitz, A.J., Rose, E.A., Gelijns, A.C., Lowy, F.D. A prospective, multicenter study of ventricular assist device infections. Circulation 127(6):691-702, 2013

Uhlemann, A-C, Kennedy, A.D., Martens, C., Porcella, F.C. DeLeo, F.R. and Lowy, F.D. Towards an understanding of evolution of Staphylococcus aureus strain USA300 during colonization in community households. Genome Biol Evol. 12:1275-85, 2012

Uhlemann, A.C., Porcella, S.F., Trivedi, S., Sullivan, S.B., Hafer, C., Kennedy, A.D., Barbian, K.D., McCarthy, A.J., Street, C., Hirschberg, D.L., Lipkin, W.I., Lindsay, J.A., DeLeo, F.R., and Lowy, F.D.  Identification of a highly transmissible animal-independent Staphylococcus aureus ST398 with distinct genomic and cell adhesion properties. mBio 3, 2012.

Gwizdala, R., Miller, M., Bhat, M., Vavagiakis, P., Henry, C., Neaigus, A., Shi, Q. and Lowy, F.D. Staphylococcus aureus among drug users: identification of hidden networks. Amer. J. Pub. Health. 2011 Jul;101(7):1268-76.

Arrecubieta, C., Francis, F.A.T.,von Bayern, M. P., Akashi, H., Deng, M.C., Naka, Y. and Lowy, F.D. SdrF, a Staphylococcus epidermidis surface protein, contributes to the initiation of ventricular assist devicedriveline-related infections. PLoS Pathogens 5:e1000411-1000424, 2009

Lowy F.D. Staphylococcus aureus infections. N Engl J Med. 1998;339:520-532

OFFICE INFORMATION:
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, 9-458
New York, NY 10032
Tel: 212-305-7185
Fax: 212-305-5794
E-mail: fl189@columbia.edu

 

Back to Top

 

NAME: Wendy McGahee, MD


ACADEMIC TITLE:
Adjunct Instructor in Clinical Medicine

EDUCATION:
Long Island University, BS, 1985
Morehouse School of Medicine, MD, 1995

SPECIALTY: General infectious diseases, substance abuse

OFFICE INFORMATION:
St. Luke's–Roosevelt Hospital Center
Addiction Institute of New York
Clark 6–Detoxification Unit
1111 Amsterdam Avenue
New York, NY 10025
E-mail: Wme150@columbia.edu

 
   

Back to Top

 

NAME: Benjamin A. Miko, MD, MS

ACADEMIC TITLE:
Assistant Professor of Medicine at CUMC

EDUCATION:
Boston University, BA, 2003
Boston University School of Medicine, MD, 2006
Columbia University Mailman School of Public Health, MS, 2012


SPECIALTY: Infectious diseases in immunocompromised hosts, staphylococcal infections, general infectious diseases, HIV primary care, MRSA molecular epidemiology

RESEARCH SUMMARY: Benjamin Miko is Assistant Professor of Medicine in the Division of Infectious Diseases at Columbia University Medical Center. His research interests focus on the molecular epidemiology of methicillin resistant Staphylococcus aureus (CA-MRSA) in both healthcare and community settings. His previous studies have evaluated the role of environmental contamination and multiple body site colonization on the risk of S. aureus transmission and infection. He remains actively engaged in research to reduce the incidence of staphylococcal infections in New York State maximum security prisons. His clinical interests include management of infectious complications of solid organ transplantation, bone marrow transplantation, and hematological malignancies. He also specializes in the treatment of staphylococcal infections, general infectious diseases, and HIV/AIDS.

SELECTED PUBLICATIONS:
Befus MB, Miko BA, Herzig CT, Keleekai N, Mukherjee DV, Larson E, Lowy FD. HIV and colonization with Staphylococcus aureus in two maximum-security prisons in New York State. J Infect. 2016 Sep 1. pii: S0163-4453(16)30220-1. [Epub ahead of print].

Befus M, Mukherjee DV, Miko BA, Herzig CTA, Bai R, Appa ZL, Lowy FD, Larson EL. Obesity as a Determinant of Staphylococcus aureus Colonization among Maximum Security Prisoners in New York State. Am J Epidemiol. Published online ahead of print.

Miko BA, Befus M, Herzig CTA, Mukherjee DV, Apa ZL, Bai RY, Tanner JP, Gage D, Genovese M, Koenigsmann CJ, Larson EL, Lowy FD. Epidemiological and Biological Determinants of Staphylococcus aureus Clinical Infection in New York State Maximum Security Prisons. Clin Infect Dis. 2015;61:203-210.

Weinberg A, Miko B, Beck J, Bacchetta M, Monegro L. Is it safe to leave an ECMO circuit primed? Perfusion. 2015;30:49-9.

Miko BA, Kamath SS, Cohen BA, Jeon C, Jia H, Larson EL. Epidemiologic Associations Between Short-Bowel Syndrome and Bloodstream Infection Among Hospitalized Children. J Pediatric Infect Dis Soc. 2015 Sep;4(3):192-7. Epub 2014 Aug 11.

Miko BA, Cohen B, Haxall K, Conway L, Kelly N, Stare D, Tropiano C, Gilman A, Seward SL, Larson E. Personal and household hygiene, environmental contamination, and health in undergraduate residence halls in New York City, 2011. PLoS One. 2013;8:e81460

Uhlemann AC, Hafer CA, Miko BA, Sowash M, Sullivan SB, Shu Q, Lowy FD. Emergence of ST398 as a community and healthcare-associated methicillin-susceptible Staphylococcus aureus in Northern Manhattan. Clin Infect Dis. 2013;57:700-3.

Miko BA, Herzig CTA, Mukherjee DV, Befus M, Apa ZL, Bai RY, Lee CJ, Uhlemann AC, Larson EL, Lowy FD. Is Environmental Contamination Associated with Staphylococcus aureus Clinical Infection in Maximum Security Prisons? Infect Control Hosp Epidemiol. 2013;34:540-2. 

Miko BA, Hafer CA, Lee CJ, Sullivan SB, Hackel MAM, Johnson BM, Whittier S, Della-Latta P, Uhlemann AC, Lowy FD. Molecular Characterization of Methicillin-Susceptible Staphylococcus aureus Clinical Isolates in the United States, 2004 to 2010. J Clin Microbiol. 2013;54:874-9.

Miko BA, Uhlemann AC, Gelman A, Lee CJ, Hafer CA, Sullivan SB, Shi Q, Miller M, Zenilman J, Lowy FD. High prevalence of colonization with Staphylococcus aureus clone USA300 at multiple body sites among sexually transmitted diseases clinic patients: An unrecognized reservoir. Microbes Infect. 2012;14:1040-3.

Miko BA, Cohen B, Conway L, Gilman A, Seward SL, Larson E. Determinants of Personal and Household Hygiene among College Students in New York City, 2011. Am J Infect Control. 2012;40:940-5.

Lat A, Bhadelia N, Miko B, Furuya EY, Thompson GR. Invasive Aspergillosis After Pandemic (H1N1) 2009. Emerg Infect Dis. 2010;16:971-973.

Sandora TH, Desai R, Miko BA, Harper MB. Assessing quality indicators for pediatric community-acquired pneumonia. Am J Med Qual. 2009;24:419-427. Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of Autoreactive B cells by CpG dsDNA. Immunity. 2003;19:837-847.

OFFICE INFORMATION:
Columbia University Medical Center
630 West 168th Street, Box 82
New York, NY 10032
Tel: 212-305-5138
Fax: 212-305-2843
E-mail: bm2266@columbia.edu

Back to Top

 

Ellen Morrison, MD, MPH

NAME: Ellen Morrison, MD, MPH

ACADEMIC TITLE:
Assistant Professor of Medicine and Epidemiology at CUMC

EDUCATION:
Olivet Nazarene College, BA, 1979
Washington University School of Medicine, MD, 1984
Columbia University Mailman School of Public Health, MPH, 1996

SPECIALTY: General infectious diseases, HIV/AIDS testing and treatment, sexually transmitted diseases, infections in pregnancy.  Dr Morrison is Chair of the Quality and Patient Safety committee for the Comprehensive Health Program at New York-Presbyterian Hospital, the Faculty Coordinator for the Edendale International elective Internal Medicine Housestaff training program, and Chief of Service for the New York-Presbyterian Hospital Infectious Diseases Service.

RESEARCH SUMMARY: Dr. Morrison has research interests in the areas of HIV testing and linkage to care, and HIV treatment and disease.

SELECTED PUBLICATIONS:
Ellman TM,
Sexton ME, Warshafsky D, Sobieszczyk ME, Morrison EA. A forgotten population: older adults with newly diagnosed HIV. AIDS Patient Care STDS. 2014 Oct;28(10):530-6. doi: 10.1089/apc.2014.0152. Epub 2014 Sep 11.

Christopoulos KA, Schackman BR, Lee G, Green RA, Morrison EA. Results from a New York City emergency department rapid HIV testing program. J Acquir Immune Defic Syndr. 2010 Mar;53(3):420-2.

Ellman TM, Sexton ME, Warshafsky D, Sobieszcyk ME, Morrison EAB. A Forgotten Population:  Older Adults with Newly Diagnosed HIV. AIDS Patient Care and STDs 2014;28:530-6.

Christopoulos KA, Schackman BR, Lee G, Green RA, Morrison EA.  Results from a New York City Emergency Department Rapid HIV Testing Program. JAIDS 2010;53:420-2.

Morrison EAB and Levenson J. Medical Treatment and Occupational Exposure. In: Fernandez F and Ruiz P, eds. Psychiatric Aspects of HIV/AIDS. Philadelphia: Lippincott Williams and Wilkins; 2006:23-35.

Morrison EAB et al. Development of a multi-item scale to quantitatively assess sexual behaviors and the transmission of high and low risk human papillomaviruses. Sex Trans Dis. 1998;25:509-515.

Morrison EAB et al. Pregnancy and cervical infection with human papillomaviruses. Int J Gyn Obstet. 1996;54:125-130.

Morrison EAB et al. Quantitation may improve clinical utility. J Clin Micro. 1992;30:2539-2543.

Morrison EAB et al. Self-administered home cervicovaginal lavage: A novel tool for the clinical/epidemiological investigation of genital HPV Infections. Am J Obstet Gynecol. 1992;167:104-107.

Morrison EAB et al. Human papillomavirus infection and other risk factors for cervical neoplasia: A case control study. Int J Cancer. 1991;49:6-13.

OFFICE INFORMATION:
Harkness Pavilion, 6th Floor
180 Fort Washington Avenue
New York, NY 10032
Tel: 212-305-6328
E-mail: eam6@cumc.columbia.edu

 

 

 

 

NAME: Julie E. Myers, MD, MPH

ACADEMIC TITLE:
Instructor in Clinical Medicine

EDUCATION:
Yale University, BS (Biology), 1996
Weill Medical College of Cornell University, MD, 2003
Columbia University Mailman School of Public Health, MPH in Epidemiology, 2011

SPECIALTY: HIV therapy and HIV prevention

RESEARCH SUMMARY: Dr. Myers is an Instructor in Clinical Medicine in the Division of Infectious Diseases. She holds the position of Director of HIV Prevention in the Bureau of HIV/AIDS Prevention and Control at the New York City Department of Health and Mental Hygiene. Dr. Myers’ primary research interests include biomedical HIV prevention and various aspects of HIV testing, including the use of self-testing. She previously worked in the Dominican Republic where she investigated treatment outcomes among HIV-infected individuals entering care.

SELECTED PUBLICATIONS:
Myers JE, El-Sadr Davis OY, Weinstein ER, Edelstein A,
Khawja A, Schillinger JA. Availability, Accessibility, and Price of Rapid HIV Self-Tests, New York City Pharmacies, Summer 2013. AIDS Behav. 2016, [Epub ahead of print].

Braunstein SL, Robertson MM, Myers J, Abraham B, Nash D. Increase in CD4+ T-Cell Count at the Time of HIV Diagnosis and Antiretroviral Treatment Initiation Among Persons With HIV in New York City. J Infect Dis. 2016;214(11):1682-6.

Braunstein SL, Robertson MM, Myers J, Nash D. Using HIV Viral Load from Surveillance to Estimate the Timing of Antiretroviral Therapy Initiation. J Acquir Immune Defic Syndr. 2016;73(2):222-7.

Myers JE, Ellman TM, Westhoff C. Injectable agents for pre-exposure prophylaxis: lessons learned from contraception to inform HIV prevention. Curr Opin HIV AIDS. 2015;10(4):271-7.

Myers JE, Xia Q, Torian LV, Irvine M, Harriman G, Sepkowitz KA, Shepard CW. CD4 Count Monitoring Frequency and Risk of CD4 Count Dropping Below 200 cells/mm3 Among Stable HIV-Infected Patients in New York City, 2007-2013. J Acquir Immune Defic Syndr. 2015;71(3):e73-8.

Ramaswamy C, Ellman TM, Myers J, Madsen A, Sepkowitz K, Shepard C. Human Immunodeficiency Virus Infection Newly Diagnosed at Autopsy in New York City, 2008-2012. Open Forum Infect Dis. 2015;2(4):ofv146.

Ransome Y, Terzian A, Addison D, Braunstein S, Myers J, Abraham B, Nash D. Expanded HIV testing coverage is associated with decreases in late HIV diagnoses. AIDS. 2015;29(11):1369-78.

Edelstein ZR, Myers JE, Cutler B, Blum M, Muzzio D, Tsoi BW. HIV Testing Experience in New York City: Offer of and Willingness to Test in the Context of New Legal Support of Routine Testing. J Acquir Immune Defic Syndr. 2015;68 Suppl 1: S45-S53.

Irvine MK, Chamberlin SA, Robbins RS, Myers JE, Braunstein SL, Mitts BJ, Harriman GA, Laraque F, Nash D. Improvements in HIV care engagement and viral load suppression following enrollment in a comprehensive HIV care coordination program. Clin Infect Dis. 2015;60(2):298-310.

Myers JE, Bodach S, Cutler BH, Shepard CW, Philippou C, Branson BM. Acceptability of home self-tests for HIV in New York City, 2006. Am J Public Health. 2014;104(12):e46-8.

McMahon JM, Myers JE, Kurth AE, Cohen SE, Mannheimer SB, Simmons J, Pouget ER, Trabold N, Haberer JE. Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the Unities States: opportunities and challenges. AIDS Patient Care and STDs, in press.

Myers JE, Sepkowitz KA. A Pill for HIV Prevention: Deja Vu All Over Again? Clin Infect Dis. 2013;56(11):1604-12.

Myers JE, El-Sadr WM, Zerbe A, Branson BM. Rapid HIV self-testing: long in coming but opportunities beckon. AIDS 2013;27(11):1687-95.

Kessler J, Myers JE, Nucifora KA, Mensah N, Kowalski A, Sweeney M, Toohey C, Khademi A, Shepard C, Cutler B, Braithwaite RS. Averting HIV infections in New York City: a modeling approach estimating the future impact of additional behavioral and biomedical HIV prevention strategies. PLoS One. 2013;8(9):e73269.

Rucinski KB, Mensah NP, Sepkowitz KA, Cutler BH, Sweeney MM, Myers JE. Knowledge and Use of Pre-Exposure Prophylaxis Among an Online Sample of Young Men Who Have Sex with Men in New York City. AIDS Behav. 2013;17(6):2180-4..

Myers JE, Braunstein SL, Shepard CW, Cutler BH, Mantsios A, Sweeney MM, Tsoi BW. Assessing the impact of a community-wide HIV testing scale-up initiative in a major urban epidemic. JAIDS 2012;61(1):23-31.

Jenness S, Myers JE, Neaigus A, Lulek J, Navejas M, Raj-Singh S. Delayed Entry into HIV Medical Care after HIV Diagnosis. AIDS Care 2012; 24(10):1240-8.

Myers JE, Myers R, Wheat M, Yin MT. Dental students and blood-borne pathogens: occupational exposures, knowledge, attitudes. J Dent Edu. 2012;76(4):479-86.

Myers JE, Taylor BS, Rojas Fermín RA, Reyes EV, Vaughan C, José L, Javier C, Franco Estévez R, Donastorg Cabral Y, Batista A, Coakley E, Lie Y, Hammer SM, Brudney KF. Transmitted drug-resistance among antiretroviral naïve patients with established HIV-1 infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literature. AIDS Res Hum Retroviruses. 2012;8(7):667-74.

Myers JE, Tsiouris SJ. Is there a place for directly observed therapy in HAART? Lancet. 2009;374:2030-2032.

OFFICE INFORMATION:

Department of Medicine

Division of Infectious Diseases

630 West 168th Street, P&S Box 82

New York, NY 10032

Tel: 212-305-7185

Fax: 212-305-7290

E-mail: jem2200@columbia.edu

 

Susan Olender, MD

NAME: Susan Olender, MD

ACADEMIC TITLE:
Assistant Professor in Clinical Medicine

EDUCATION:
SUNY at Albany, BA, 1994
NYU School of Medicine, MD, 2002
Columbia University Mailman School of Public Health, MS (Epidemiology), 2015

SPECIALTY: HIV primary care

RESEARCH SUMMARY: Dr. Susan Olender is the Associate Medical Director of the Comprehensive Health/HIV Program at New York Presbyterian Hospital. Her research interests include healthcare delivery and redesign, HIV engagement in care and care coordination with a particular focus on traditionally hard to reach populations, members of racial/ethnic minority communities.


SELECTED PUBLICATIONS:
Taylor BS, Olender SA, Tieu HV, Wilkin TJ, CROI 2016: Advances in Antiretroviral Therapy. Top Antivir Med. 2016 May-Jun; 24(1): 59-81. PMID: 27398863

Christopoulos KA, Olender S, Lopez AM, Lekas HM, Jaiswal J, Mellman W, Geng E, Koester KA. Retained in HIV Care But Not on Antiretroviral Treatment: A Qualitative Patient-Provider Dyadic Study. PLoS Med. 2015 Aug 11;12(8):e1001863. doi:10.1371/journal.pmed.1001863. eCollection 2015 Aug. PMID: 26263532

Olender SA, Taylor BS, Wong M, Wilkin TJ. CROI 2015: Advances in Antiretroviral Therapy. Top Antivir Med. 2015 Mar-Apr;23(1):28-45.

Grossman LC, Kline MD, Scherer ML, Churnet BH, Yin MT, Olender SA, Sauer MV, Douglas NC. Survey of obstetrics and gynecology providers on management of HIV-serodiscordant couples: assessment of attitudes, practices, and knowledge. Andro Gyn: Curr Res. 2014 (2): 3

Scherer ML, Douglas NC, Churnet BH, Grossman LC, Kline M, Yin MT, Sauer MV, Olender SA. “Survey of HIV care providers on management of HIV serodiscordant couples - assessment of attitudes, knowledge, and practices.” AIDS Care. 2014;26(11):1435-9.

Schnall R, Clark S, Olender S, Sperling JD. Providers' perceptions of the factors influencing the implementation of the New York State mandatory HIV testing law in two Urban academic emergency departments. Acad Emerg Med 2013; 20(3):279-86.

Olender S, Wilkin TJ, Taylor BS, Hammer SM.  Advances in antiretroviral therapy.  Topics in Antiviral Medicine, 2012; 20:61-86.

Shalev N, Olender SA, Chiasson MA. “Targeted anal cancer screening in HIV-infected patients: prevalence of screening indicators.” AIDS, 2009;23(12):1613-5.

Sasadeusz J, Audsley J, Mijch A, Baden R, Caro J, Hunter H, Matthews G, McMahon MA, Olender SA, Siliciano RF, Lewin SR, Thio CL. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naïve patients. AIDS, 2008; 22(8):947-55.

Wilkin TJ, Taylor B, Olender S, Hammer SM. Advances in Antiretroviral Therapy. Topics in HIV Medicine, 2008; 16:31-60. http://www.iasusa.org/pub/topics/2008/issue1/31.pdf

Chiasson MA, Massad LS, Olender S, Wright TC. HIV Infection in Women in Atlas of AIDS. Mandell GL and Mildvan D editors, Fourth Edition. Current Medicine, 2007.

Olender S, Saito M, Apgar J, Gillenwater K, Bautista CT, Lescano AG, Moro P, Caviedes L, Hsieh EJ, Gilman RH. Low prevalence and increased household clustering of Mycobacterium tuberculosis infection in high altitude villages in Peru. American Journal of Tropical Medicine and Hygiene, 2003; 68:721-727.

OFFICE INFORMATION:
Harkness Pavilion, 6th Floor
180 Fort Washington Avenue
New York, NY 10032
Tel: 212-305-3174
Fax: 212-305-7692
E-mail: so2045@columbia.edu

 

Back to Top

 

parry jpg

 

NAME: Michael Parry, MD

ACADEMIC TITLE:
Adjunct Professor of Clinical Medicine


EDUCATION:
Yale University, BA, 1966
Columbia College of Physicians and Surgeons, MD, 1970

SPECIALTY: General infectious diseases, hospital epidemiology and infection prevention, travel medicine

SELECTED PUBLICATIONS:
Parry MF, Grant B and Sestovic M. Successful Reduction in Catheter Associated Urinary Tract Infections: Focus on Nurse-directed Catheter Removal. American Journal of Infection Control, 2013; 12:1178-1181

Bishop J, Parry MF and Hall, T.  Decreasing Clostridium difficile Infections in Surgery:  Impact of a Practice Bundle. Incorporating a Resident Rounding Protocol.  Connecticut Med. 2013;77:69-75.

Tejwani, R and Parry MF. Antimicrobial Lock Therapy as an Adjunct to Management of Catheter-related Bacteremia:A Community Hospital Experience. Infectious Diseases in Clinical Practice. 2011:19, 256-261.

Carling, PC., Parry MF, Bruno-Murtha, LA, Dick, B. Improving Environmental Hygiene in 27 Intensive Care Units to Decrease Multidrug-Resistant Bacterial Transmission. Critical Care Medicine 2010. 38:1054-1059.

Carling, PC., Parry MF, Rupp, ME; Po,JL, Dick, B, Von Beheren, S. Improving Cleaning of the Environment Surrounding Patients in 36 Acute Care Hospitals. Infection Control and Hospital Epidemiology 2008. 29:1035-1041.

Polgreen PM, Septimus EJ, Parry MF, Beekman SE, Cavanaugh JE, Srinivasan A, Talbot TR. Relationship of Influenza Vaccination Declination Statements and Influenza Vaccination Rates for Healthcare Workers in 22 US Hospitals. Infection Control Healthcare Epidemiology 2008. 29:675-677.

Kritchevsky SB, Braun BI, Kusek L, Wong ES, Solomon SL, Parry MF, Richards CL, Simmons BS. The Impact of Hospital Practice on Central Venous Catheter-associated Bloodstream Infection Rates at the Patient and Unit Level: a Multi-center Study. American J Medical Quality 2008. 23:24-38.

Parry MF, Wright P, Stewart J, McLeod GX, Tucker M, Weinberg A. Impact of an Adherence Program on the Health and Outlook of HIV-Infected Patients Failing Antiretroviral Therapy. Journal of the International Association of Physicians in AIDS Care 2005. 4:59-65.

Parry MF, Grant B, Iton A, Parry PD, Baranowsky D. Influenza Vaccination – A Collaborative Effort to Improve the Health of the Community. Infection Control and Healthcare Epidemiology 2004. 25:929-932.

Parry MF, Grant B, Yukna M, Adler-Klein D, McLeod G, Rosenstein C, and Taddonio R. Candida Osteomyelitis and Diskitis after Spinal Surgery. An Outbreak that Implicates Artificial Nail Use Clin Infect Dis 2001. 32:352-357.

OFFICE INFORMATION:
Stamford Hospital
30 Shelburne Road
Stamford, CT 06904
Tel: 203- 276-7487
E-mail: MParry@stamhealth.org

 

 
 

NAME: Marcus R. Pereira, MD, MPH

ACADEMIC TITLE:
Assistant Clinical Professor of Medicine

ACADEMIC TITLE: Assistant Clinical Professor of Medicine

EDUCATION:
New College of Florida, BS, 1999
Florida International University, MPH, 2000
University of Florida, MD, 2004

SPECIALTY: Transplant infectious diseases, General infectious diseases, HIV primary care

RESEARCH SUMMARY: Dr. Marcus Pereira is an Assistant Clinical Professor of Medicine at the Columbia University College of Physicians. During fellowship at Columbia University, he studied the prevalence and risk factors for chronic kidney disease among patients in our HIV clinic. He also joined Dr. Fidock's laboratory to study malaria drug resistance and in vivo PK/PD trials of antimalarial drug combinations. Establishing and leading the Transplant Infectious Diseases Program, Dr. Pereira is focused on infectious complications among transplant patients in both inpatient and outpatient settings. He is also involved in the development of infection prophylaxis and treatment protocols in immunocompromised patients. His current research includes multi-drug resistant infections, including bacterial and fungal organisms among renal and liver transplant patients.

SELECTED PUBLICATIONS:
Greendyke W, Pereira MR, “Infections complications and vaccinations in the post-transplant population”, Edited by David Sass and Alden Doyle, “Care of the Liver and Kidney Transplant Recipient”, Medical Clinics of North America, 2016 May;100(3): 587-98. Elsevier.

Pereira MR, Uhlemann AC. The evolving threat of carbapenem-resistant infections after liver transplantation: The case of Acinetobacter baumannii. Liver Transpl. 2016 May;22(5):579-81

Benamu E, Pereira MR, Delli Carpini K, Huprikar S, Taimur S, Patel G, Friedman AL, Jenkins SG, Herold BC, Madan RP: Utility of Respiratory Cultures in the Evaluation of deceased Organ Donors. Accepted for ICAAC 2015 in San Diego, CA

Pouch SM, Kubin CJ, Satlin MJ, Tsapepas DS, Lee JR, Dube G, Pereira MR. Epidemiology and outcomes of carbapenem-resistant Klebsiella pneumoniae bacteriuria in kidney transplant recipients. Transpl Infect Dis. 2015 Dec;17(6):800-9. doi: 10.1111/tid.12450. Epub 2015 Nov 5.

DeLuca IJ, Patel VA, Pereira MR, Grossman ME. A new polyomavirus-related dermatosis in a pancreatic transplant patient. JAAD Case Rep. 2015 Nov 24;1(6):S38-40. doi: 10.1016/j.jdcr.2015.09.018. eCollection 2015 Nov.

Pereira MR, Scully BF, Pouch SM, Uhlemann AC, Goudie S, Emond JE, Verna EC. Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Infections in Liver Transplant Recipients. Liver Transpl. 2015 Jul 1. [Epub ahead of print]

Gray EB, Benedict T, Rivera H, Huprikar S, Zakowski P, Kubak B, Pereira MR, Dhand A, Kransdorf EP, Stenehjem E, Katugaha S, Schmidt M, Stocks L, Delli Carpini K, Fuentes JR, Kiros LS, Montgomery S: Trypanosoma cruzi infections in solid organ transplant recipients, 2014. Accepted for oral presentation at IDWeek 2015 in San Diego, CA

Aaron JG, Pereira MR: Utilization of an Interferon-Gamma Release Assay Increases Compliance for Latent Tuberculosis Screening Among Liver Transplant Candidates: ICAAC 2014 T-1799

Mishra N, Pereira M, Rhodes RH, An P, Pipas JM, Jain K, Kapoor A, Briese T, Faust PL, Lipkin WI. Identification of a Novel Polyomavirus in a Pancreatic Transplant Recipient with Retinal Blindness and Vasculitic Myopathy. J Infect Dis. 2014 Nov 15;210(10)

Shah, S, Tsapepas D, Kubin C, Martin S, Mohan S, Ratner L, Pereira M. Kapur S, Dadhania D, Walker-McDermott J. Risk factors associated with Clostridium difficile infection after kidney and pancreas transplantation. Transplant Inf Dis 2013 Oct;15(5):502-9

Wright K, Young P, Brickman C, Sam T, Badjatia N, Pereira M, Connolly ES, Yin MT. Rates and determinants of ventriculostomy-related infections during a hospital transition to use of antibiotic-coated external ventricular drains. Neurosurg Focus. 2013 May;34(5):E12.

Brown RS Jr, Verna EC, Pereira M, Tilson HH, Aguilar C, Leu CS, Buti M, Fagan EA. Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. J Hepatol. 2012 Nov;57(5):953-9.

Pereira M, Henrich P., Sidhu A.B.S. Johnson D., Hardink J., Gore K., Wele M., Djimde A., Chandra R., Fidock D.A. Investigations into the in vivo and in vitro antimalarial properties of azithromycin-chloroquine combinations including the reversal agent amlodipine. Antimicrob Agents Chemother. 2011 Jul;55(7):3115-24.

Pereira MR, Miko B, Mehta MM, Hammer SM. “Anti-Respiratory Viral Agents,” Edited by Dougla Richman, Richard Whitley and Frederick Hayden,”Clinical Virology” Fourth Ed. Not yet published.

Kubin C, Pouch S, Tsapepas D, Dube G, Pereira M; Epidemiology and Antimicrobial Resistance in Urine Isolates Among Renal Transplant Recipients Over a 10-year Period; ICAAC 2012; T-1036

Pouch S, Kubin C, Tsapepas D, Dube G, Pereira M; Epidemiology and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae (CRKP) Bacteriuria in Renal Transplant (RT) Recipients; ICAAC 2012: T- 1034

Kumar S.T.R., Pereira M, Fidock D.A.: Inhibitors of FabI as Potential Antimalarial Prophylactic Agents; ASTMH 2009: # 520

Pereira M., Liao J., Fidock D.A.: Potentiation of Chloroquine and Azithromycin by (+)-Amlodipine in a Chloroquine-Resistant Rodent Malaria Model; ICAAC 2009: P-366

Pereira M, Miko B., Fatehi P., Brudney K., Sobieszczyk M.: Prevalence and Risk Factors of Chronic Kidney Disease in an HIV Infected Minority Population; IDSA/ICAAC 2008; H-2340.

Pereira MR, Pouch S, Scully B. “Infections in autologous & allogeneic stem cell transplantation”, Edited by Amar Safdar, “Principles and Practice of Transplant Infectious Diseases.” Elsevier, not yet published

Pereira MR, Miko B, Safdar A. “Respiratory tract infections: sinusitis, tracheobronchitis and pneumonia” Edited by Amara Safdar, “Principles and Practice of Transplant Infectious Diseases” Elsevier, not yet published

OFFICE INFORMATION:

Columbia University Medical Center

630 West 168th Street, P&S Box 82

New York, NY 10032

Tel: 212-305-7185 / 212-570-3081

Fax: 212-305-7290

E-mail: mp2323@columbia.edu

 

 

Deborah Rudin, MD

NAME: Deborah Rudin, MD

ACADEMIC TITLE:
Assistant Professor of Clinical Medicine

EDUCATION:
University of Pennsylvania, BA, 1983
Mount Sinai School of Medicine, MD, 1987

SPECIALTY: Vaccine product development

OFFICE INFORMATION:
Global Medical Director
Product Leader-Pediatric Vaccines
Global Medical Affairs, Information and Operations
Office Number: 908-423-5072

Columbia University Medical Center

630 W 168th Street, Box 82
New York, New York 10032
Tel: 212-305-7185

 

Back to Top

 

http://www.cumc.columbia.edu/dept/id/images/spacer.gif

NAME: Matthew Scherer, MD

ACADEMIC TITLE:
Instructor in Medicine

EDUCATION:
Columbia University, BA, 2003
Weill Medical College of Cornell University, MD, 2008

Specialty: General infectious diseases, HIV, HCV

Research Summary: Dr. Scherer sees patients for HIV primary care, hepatitis C care, and general infectious diseases consults. He is currently the principal investigator on a New York State AIDS Institute sponsored grant to provide linkage to hepatitis C care for difficult to reach populations. He is a co-investigator on several clinical trials at the CUMC AIDS Clinical Trials Group site.

SELECTED ABSTRACTS AND PUBLICATIONS:
Grossman LC, Kline MD, Scherer ML, Churnet BH, Yin MT, Olender SA, Sauer MV, Douglas NC. Survey of obstetrics and gynecology providers on management of HIV-serodiscordant couples: assessment of attitudes, practices, and knowledge. Andro Gyn: Curr Res. 2014 (2): 3.

Scherer ML, Douglas NC, Churnet BH, Grossman LC, Kline M, Yin MT, Sauer MV, Olender SO. Survey of HIV care providers on management of HIV serodiscordant couples- assessment of attitudes, knowledge, and practices. AIDS Care. 2014. (11): 1435-9.

Scherer ML*, Nalls MA*, Pawlikowska L, Ziv E, Mitchell GF, Huntsman S, Hu D, Sutton-Tyrrell K, Lakatta EG, Hsueh WC, Newman AB, Tandon A, Kim L, Kwok PY, Sung A, Li R, Psaty B, Reiner AP, Harris TB. Admixture mapping of ankle-arm index: identification of a candidate locus associated with peripheral arterial disease. J Med Genet. 2010. Jan;47(1):1-7 *Shared primary authorship

Scherer ML, Aspelund T, Sigurdsson S, Detrano R, Garcia M, Mitchell GF, Thorgeirsson G, Launer LJ, Gudnason V, Harris TB. Abnormal T-wave axis is associated with coronary artery calcification in older adults.  Scand Cardiovasc J. 2009 Aug; 43(4): 240-8.

Trocciola SM, Chaer RA, Lin SC, Dayal R, Scherer ML, Coll D, Kent KC, Faries PL. Embolization of renal artery aneurysm and arteriovenous fistula: a case report. Vasc Endovascular Surg 2005;39(6):525-9.

Scherer ML, Zhang CA, Zhao B, Newhouse J, McMahon DJ, Colon I, Guo X, Shane E, Yin MT. Subcutaneous fat is positively correlated with bone mineral density in HIV-positive postmenopausal women. 12th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV. 4 November 2010. Poster presentation. Abstract in Antiviral Therapy 2010; 15 Suppl 4: A38.

Scherer ML.  Admixture mapping of ankle-arm index: identification of candidate loci associated peripheral arterial disease in the Health, Aging and Body Composition Study and the Cardiovascular Health Study.  Feb 2008. Weill Cornell Medical College Student Research Day (presentation).

Scherer ML.  Lifelong cardiovascular risk factors and late life coronary artery calcification: The Age Gene/Environment Susceptibility-Reykjavik Study.  National Institute on Aging Scientific Retreat.  18 April 2007 (presentation).

Scherer ML, Sigurdsson S, Detrano R, Garcia M, Launer LJ, Karlsdottir G, Thorgeirsson G, Gudnason V, Harris TB.  T-wave axis is associated with coronary artery calcium score in an asymptomatic elderly population.  American Heart Association 47th Annual Conference on Cardiovascular Disease Epidemiology and Prevention. 1 March 2007.  Poster presentation.  Abstract in Circulation. 2007;115:e284.

OFFICE INFORMATION:

Columbia University Medical Center

630 West 168th Street, Box 82

New York, NY 10032

Tel: 212-305-8039

Fax: 212-305-7290

E-mail: mls97@columbia.edu

 

 
 

Brian Scully, MD

NAME: Brian Scully, MD

ACADEMIC TITLE:
Associate Professor of Clinical Medicine


EDUCATION:
Trinity College, Dublin University, BA, 1969
Trinity College, Dublin University, MB, BCh, BAO, 1971
Trinity College, Dublin University, MA, 1973

SPECIALTY: Nosocomial infections, transplant infectious disease

RESEARCH SUMMARY:
Dr Scully is the chair of the Infection Control Committee at NewYork–Presbyterian Hospital, and cochair of the Joint Infection Control Committee and the Joint Subcommittee on Anti-infective Use. His research interests are in nosocomial infections, transplant infectious disease, and hospital epidemiology.

SELECTED PUBLICATIONS:
Varr BC, Restaino SW, Farr M, Scully B, Colombo PC, Naka Y, Mancini DM. Infectious complications after cardiac transplantation in patients bridged with mechanical circulatory support devices versus medical therapy. J Heart Lung Transplant. 2016 Sep;35(9):1116-23. Epub 2016 May 11.

Pereira MR, Scully BF, Pouch SM, Uhlemann AC, Goudie S, Emond JE, Verna EC. Risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl. 2015 Dec;21(12):1511-9.

Weiser JA, Scully BE, Bulman WA, Husain S, Grossman ME. Periumbilical parasitic thumbprint purpura: strongyloides hyperinfection syndrome acquired from a cadaveric renal transplant. Transpl Infect Dis. 2011 Feb;13(1):58-62.

Bernstein P, Furuya Y, Steinberg S, Scully B, Larussa P, Gershon AA. Vaccine-related varicella-zoster rash in a hospitalized immunocompetent patient. Am J Infect Control. 2011 Apr;39(3):247-9. doi: 10.1016/j.ajic.2010.06.027. Epub 2011 Jan 26.

Brust JC, Whittier S, Scully BE, McGregor CC, Yin MT. Five cases of bacteraemia due to Gordonia species. J Med Microbiol. 2009 Oct;58(Pt 10):1376-8. Epub 2009 Jun 15.

Farr M, Rubin AI, Mangurian C, Scully B et al. Late syphilis in cardiac transplant patient. J Heart Lung Transplant. 2006 25(3): 358-61.

Haas S, Scully B, Cohen D, Radhakrishnan J. Mycobacterium avium complex infection in kidney transplant patients. Transpl Infect Dis. 2005 7(2):75-9.


OFFICE INFORMATION:
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Tel: 212-305-7185
Fax: 212-305-7290

 

Back to Top

 

NAME: Noga Shalev, MD

ACADEMIC TITLE:
Assistant Professor of Medicine

EDUCATION:
University of California, Berkeley, BA, 1996
NYU School of Medicine, MD, 2003

SPECIALTY: HIV primary care, correctional medicine

RESEARCH SUMMARY:
Dr. Noga Shalev is an Assistant Professor in Clinical Medicine in the Infectious Diseases Division at the Columbia University College of Physicians. Her research focuses on the evaluation of medical care in correctional settings and its impact on health inequities.

SELECTED PUBLICATIONS:
Taylor BS, Shalev N, Wilkin TJ. CROI 2014: advances in antiretroviral therapy. Top Antivir Med. 2014 May;22(2):616-31.

Taylor BS, Wilkin TJ, Shalev N, Hammer SM. CROI 2013: Advances in antiretroviral therapy. Top Antivir Med. 2013 Apr-May;21(2):75-89. Review.

Shalev N, Mackenzie S. Correlation between imprisonment rates and new HIV/AIDS diagnoses. Presented at the 19th International AIDS Conference, Washington, DC. July 2012.

Ammassari A, Trotta MP, Shalev N, Marconi P, Antinori A. Beyond virological suppression: the role of adherence in the late HAART era." Antivir Ther. 2012;17(5):785-92.

Ammassari A, Trotta MP, Shalev N, Tettoni MC, Maschi S, Di Sora F, Orofino G, d'Ettorre G, Bai F, Celesia MB, Roldan EQ, Maserati R, Sterrantino G, Tommasi C, Boumis E, Iardino MR, Antinori A. Timed short messaging service improves adherence and virological outcomes in HIV-1-infected patients with suboptimal adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2011;58(4):e113-5.

Wilkin TJ, Shalev N, Tieu HV, Hammer SM. Advances in antiretroviral therapy. Top HIV Med. 2010 Apr-May;18(2):66-92. Review.

Shalev N, Chiasson MA, Dobkin JF, Lee G. Characterization of medical providers to jail inmates in New York State. Am J Public Health. Accepted for publication July 2010.

Shalev N, Olender SA, Chiasson MA. Targeted anal cancer screening in HIV-infected patients: prevalence of screening indicators. AIDS. 2009 Jul 31;23(12):1613-5.

Shalev N. From public to private care the historical trajectory of medical services in a New York city jail. Am J Public Health. 2009;99(6):988-95.

Kluger M, Shalev N, Capponi L, Heinzerling K. Designing a clinical hepatitis screening and prevention program. 4th National Harm Reduction Conference, Seattle, WA, December 2002

Heinzerling K, Shalev N. Brief interventions to reduce harmful injection practices among drug users in health care settings. 4th National Harm reduction Conference, Seattle, WA December 2002

OFFICE INFORMATION:
Harkness Pavilion, 6th Floor
180 Fort Washington Avenue
New York, NY 10032
Tel: 212-305-4707
Fax: 212-305-7692
E-mail: ns2413@columbia.edu

 

Back to Top

 


http://www.cumc.columbia.edu/dept/id/images/spacer.gif

NAME: Angela Gomez-Simmonds, MD, MS

ACADEMIC TITLE:
Instructor in Medicine

EDUCATION:
University of Pennsylvania, BA, 2003

New Jersey Medical School, UMDNJ, MD, 2008
Mailman School of Public Health, Columbia University, MS, 2015


SPECIALTY:
General infectious diseases, molecular epidemiology of MDR gram-negative bacteria

RESEARCH SUMMARY: Dr. Gomez-Simmonds’ research interests entail understanding the molecular factors that potentiate the acquisition and dissemination of multidrug resistance among hospital-associated pathogens. She is currently working in Dr. Anne-Catrin Uhlemann’s laboratory, where she has been focusing on developing sequencing-based methods for investigating the epidemiology and transmission of a broad range of MDR gram-negative bacteria at CUMC. She is particularly interested in describing the repertoire of resistance gene and associated mobile genetic elements in these pathogens. Additional research interests include identifying clinical risk factors and optimal therapeutic regimens for MDR gram-negative infections.

SELECTED PUBLICATIONS:
Gomez-Simmonds A, Greenman M, Sowash M, Sullivan SB, Tanner J, Uhlemann AC. Population structure of Klebsiella pneumoniae causing bloodstream infections at a New York City tertiary care hospital: diversification of multidrug-resistant isolates. Journal of Clinical Microbiology 2015; 53:2060-7.

Gomez-Simmonds A, Nelson B, Eiras D, Loo A, Jenkins SG, Whittier S, Calfee DP, Satlin M, Kubin CJ, Furuya EY. Monotherapy versus combination therapy for the treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Poster presentation, Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2014.

Gomez-Simmonds A, Kubin CJ, Furuya EY. Comparison of 3 severity criteria for Clostridium difficile infection. Infection Control Hospital Epidemiology 2014;35:196-9.

OFFICE INFORMATION:
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, 9-458
New York, NY 10032
Tel: 212-305-9322
Fax: 212-305-5794

 

Back to Top

 

Magdalena Sobieszczyk, MD

http://www.cumc.columbia.edu/dept/id/images/spacer.gif

NAME: Magdalena Sobieszczyk, MD, MPH

ACADEMIC TITLE:
Associate Professor of Medicine

EDUCATION:
Harvard University, BA
Columbia College of Physicians and Surgeons, MD
Columbia University Mailman School of Public Health, MPH

SPECIALTY: HIV vaccine trials, international HIV, metabolic complications of HIV therapy

RESEARCH SUMMARY: Dr. Magdalena Sobieszczyk is an Associate Professor of Medicine in the Infectious Diseases Division at the Columbia University College of Physicians. She is the PI of the NIH-funded Columbia HVTN and ACTG Clinical Research Site.  Her research focuses on developing, testing, and implementation of biomedical strategies to prevent HIV infection, specifically preventive HIV vaccines and pre-exposure prophylaxis (PrEP).  Particular interests include assessing combination biomedical prevention strategies such as vaccines together with oral and topical PrEP; and evaluating host factors influencing immunologic and virologic course of HIV disease and response to vaccination in study participants. She has been involved in the development and implementation of several international and national HIV prevention protocols and is the co-chair of phase 2b HIV vaccine protocol to determine the safety and efficacy of the DNA prime-Ad5 boost vaccine regimen in individuals at risk of HIV infection (HVTN 505).

Her research with HIV infected individuals includes investigating HIV testing and linkage to care in the predominantly Latino communities of northern Manhattan. This also includes describing the prevalence of metabolic and renal abnormalities in this population and in South African cohorts.

Dr. Sobieszczyk is also a co-investigator of the Centre for the AIDS Program of Research in South Africa (CAPRISA) project entitled “Viral Setpoint and Clinical Progression in HIV-1 Subtype C Infection: The Role of Immunological and Viral Factors During Acute and Early Infection” (Salim Abdool Karim, PI). 

SELECTED ABSTRACTS AND PUBLICATIONS:
Sobieszczyk ME, Werner L, Mlisana K, Naicker N, Feinstein A, Gray CM, Masson L, Passmore JS, Williamson C, Karim QA, Abdool Karim SS, Garret NJ. Metabolic syndrome after HIV acquisition in South African women. J Acquir Immune Defic Syndr. 2016 Jul 6. [Epub ahead of print]

Williams WB, Liao HX, Moody MA, Kepler TB, Alam SM, Gao F, Wiehe K, Trama AM, Jones K, Zhang R, Song H, Marshall DJ, Whitesides JF, Sawatzki K, Hua A, Liu P, Tay MZ, Seaton KE, Shen X, Foulger A, Lloyd KE, Parks R, Pollara J, Ferrari G, Yu JS, Vandergrift N, Montefiori DC, Sobieszczyk ME, Hammer S, Karuna S, Gilbert P, Grove D, Grunenberg N, McElrath MJ, Mascola JR, Koup RA, Corey L, Nabel GJ, Morgan C, Churchyard G, Maenza J, Keefer M, Graham BS, Baden LR, Tomaras GD, Haynes BF. HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science. 2015 Aug 14;349(6249):aab1253. Epub 2015 Jul 30.

Dawson L, Garner S, Anude C, Ndebele P, Karuna S, Holt R, Broder G, Handibode J, Hammer S, Sobieszczyk ME. Testing the waters: ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial. Clinical trials. Apr 7, 2015.

Ellman TM, Hawkins K, Benitez J, Negron R, Chang S, Palmer S, Robertson V, Chiasson MA, Sobieszczyk ME. Representation of Latino and Black Men and Transgender women Screening and Enrolling into Preventive HIV Vaccine Trials in New York City. Vaccine. 2015;33(48):6809-15. PMID:26458799

Tang E., Sobieszczyk ME., Shu E., Gonzalez P., Sanchez J., Lama J. Provider Attitudes toward Oral Pre-Exposure Prophylaxis for HIV Prevention among High-Risk MSM in Lima, Peru. AIDS Research and Human Retroviruses 30(5):416-24.2014

Ellman TM, Sexton ME, Warshafsky D, Sobieszczyk ME, Morrison E.  A Forgotten Population: Older Adults Newly-Diagnosed with HIV. AIDS Patient Care and STDs. Volume 28, Number 10, 2014

Hammer S.M., Sobieszczyk ME, Janes H. et al. Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. New England J of Medicine, 2013 10.1056/NEJMoa1310566.

Tieu HV, Rolland M, Hammer SM, Sobieszczyk ME. Translational Research Insights from Completed HIV Vaccine Efficacy Trials. Journal of AIDS 2013; (63) Supplement 2, July 1

Mlisana K, Sobieszczyk ME, Loggerenberg F, Feinstein A, Werner L, Feinstein A, Williamson C, Loggerenberg F, Karim S. Challenges of diagnosing acute HIV-1 subtype C infection in African women: Performance of a clinical algorithm and the need for point-of-care nucleic acid based testing. PLoS ONE 2013; 8(4): e62928.

Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk ME, and Hammer SM. In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Nonvaccine Prevention Modalities. AIDS Research and Human Retroviruses 2013. ahead of print. doi:10.1089/aid.2012.0385

Sobieszczyk ME, Lingappa J, McElrath JM. Host genetic polymorphisms associated with innate immune factors and HIV-1. Curr Opinion HIV/AIDS 2011; 6 (5): 427-434

OFFICE INFORMATION:

Department of Medicine

Division of Infectious Diseases

630 West 168th Street, Box82

New York, NY 10032

Tel: 212-305-7185

Fax: 212-305-7290

E-mail: mes52@columbia.edu

 

 

Back to Top

 

hong

NAME: Hong Van Tieu, MD, MS

ACADEMIC TITLE:
Associate Professor of Medicine

EDUCATION:
University of Pennsylvania, BS, 1996
Mount Sinai School of Medicine, MD, 2001
Columbia University Mailman School of Public Health, MS, 2009

SPECIALTY: HIV epidemiology, HIV biomedical prevention interventions

RESEARCH SUMMARY: Dr. Hong Van Tieu isanAssistant Professor inClinical Medicine in the Division of Infectious Diseases at Columbia University, as well as an Associate Member in the Laboratory of Infectious Disease Prevention at the New York Blood Center. During fellowship at Columbia University, she studied immunologic markers to predict and diagnose tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and TB co-infected adults in Thailand. Dr. Tieu previously served as a co-investigator for the HIV Prevention Trials Network (HPTN) 061 study to test the feasibility and acceptability of a multi-component intervention to prevent HIV infection among Black men who have sex with men (MSM). She is a Principal Investigator of an NIH NIDA K01 career development award to study how sexual networks influence HIV risk among MSM in New York City (NYC) using social network analysis and qualitative methods. She has been involved in HIV vaccine clinical research studies as Site Principal Investigator at the New York Blood Center, in collaboration with the Columbia University HIV Vaccine Trials Unit.  In addition, Dr. Tieu is a Site Principal Investigator of a Phase 2 study examining safety and tolerability of a long-acting injectable integrase inhibitor to be used for HIV pre-exposure prophylaxis. Dr. Tieu is currently leading two studies: (1) a pilot study examining the use of self-administered rectal swabs for HIV-1 RNA and Y Chromosome DNA detection among a MSM in NYC as biological markers for HIV exposure and condomless receptive anal sex, and (2) an epidemiologic study mapping the prevalence of Hepatitis C virus infections among MSM in NYC, with use of avidity assays to determine recent infections and phylogenetic analysis to assess clustering of infections.

SELECTED ABSTRACTS AND PUBLICATIONS:
Koblin BA, Egan JE, Nandi V, Sang JM, Cerdá M, Tieu HV, Ompad DC, Hoover DR, Frye V. Congruence of Home, Social and Sex Neighborhoods among Men Who Have Sex with Men, NYCM2M Study. J Urban Health. 2016 Sep 19. [Epub ahead of print]

Taylor BS, Olender SA, Tieu HV, Wilkin TJ. CROI 2016: Advances in Antiretroviral Therapy. Top Antivir Med. 2016 May-Jun;24(1):59-81.

Tieu HV, Nandi V, Hoover DR, Lucy D, Stewart K, Frye V, Cerda M, Ompad D, Latkin C, Koblin BA; NYC M2M Study Team. Do Sexual Networks of Men Who Have Sex with Men in New York City Differ by Race/Ethnicity? AIDS Patient Care STDS. 2016 Jan;30(1):39-47. doi: 10.1089/apc.2015.0237.

Tieu HV, Liu TY, Hussen S, Connor M, Wang L, Buchbinder S, Wilton L, Gorbach P, Mayer K, Griffith S, Kelly C, Elharrar V, Phillips G, Cummings V, Koblin B, Latkin C, HPTN 061. Sexual Networks and HIV Risk among Black Men Who Have Sex with Men in 6 U.S. Cities. PLoS One 2015;10(8):e0134085.

Tieu HV, Suntarattiwong P, Puthanakit T, Chotpitayasunondh T, Chokephaibulkit K, Sirivichayakul S, Buranapraditkun S, Rungrojrat P, Chomchey N, Tsiouris S, Hammer S, Nandi V, Ananworanich J; Thai TB Px Study Group. Comparing interferon-gamma release assays to tuberculin skin test in Thai children with tuberculosis exposure. PLoS One 2014;9(8):e105003.

Tieu HV, Nandi V, Frye V, Stewart K, Oquendo H, Bush B, Cerda M, Hoover DR, Ompad D, Koblin BA. Concurrent Partnerships and HIV Risk among Men Who Have Sex with Men in New York City. Sexually Transmitted Diseases 2014:41(3):200-8.

Tieu HV, Li X, Donnell D, Vittinghoff E, Buchbinder S, Parente ZG, Koblin BA. Anal Sex Role Segregation and Versatility among Men Who Have Sex with Men: EXPLORE Study. JAIDS 2013;64(1):121-125.

Tieu HV, Rolland M, Hammer S, Sobieszczyk ME. Translational Research Insights from Completed HIV Vaccine Efficacy Trials. JAIDS 2013:63 Suppl 2:S150-4.

Tieu HV, Spikes P, Patterson J, Bonner S, Egan JE, Goodman K, Stewart K, Frye V, Xu G, Hoover DR, Koblin BA. Sociodemographic and Risk Behavior Characteristics Associated with Unprotected Sex with Women among Black Men Who Have Sex with Men and Women in New York City. AIDS Care 2012;24(9):1111-9.   

Koblin BA, Tieu HV, Frye V. Disparities in HIV/AIDS in black men who have sex with men. Lancet. 2012 Jul 28;380(9839):316-8. Epub 2012 Jul 20.

Tieu HV, Xu G, Bonner S, Spikes P, Egan JE, Goodman K, Stewart K, Koblin BA. Sexual Partner Characteristics, Serodiscordant/Serostatus Unknown Unprotected Anal Intercourse and Disclosure among HIV-infected and Uninfected Black Men Who Have Sex with Men in New York City. Sexually Transmitted Diseases 2011;38(6):548-54.  

Tieu HV, Murrill C, Xu G, Koblin BA.  Sexual Partnering and HIV Risk among Black Men Who Have Sex With Men: New York City. Journal of Urban Health 2010;87:113-21. 

Tieu HV, Phanuphak N, Ananworanich J, Vatanparast R, Jadwattanakul T, Pharachetsakul N, Mingkwanrungrueng P, Buajoom R, Teeratakulpisarn , Hammer SM, Chiasson MA, Phanuphak P.  Acceptability of Circumcision for the Prevention of HIV Among High-risk Heterosexual Men in Thailand. Sexually Transmitted Diseases 2010;37:352-5.

Manosuthi W, Tieu HV, Tantanathip P, Mankatitham W, Lueangniyomkul A, Ananworanich J, Avihingsanon A, Siangphoe U, Klongugkara S, Thawornwan U, Suntisuklappon B, Sungkanuparph S, for the N2R Study Team. Clinical Case Definition and Manifestations of Paradoxical Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome. AIDS 2009;23:2467-71.

Tieu HV, Ananworanich J, Avihingsanon A, Apateerapong W, Sirivichayakul S, Klongugkara S, Boonchokchai B, Siangphoe U, Hammer S, Manosuthi W.  Immunologic Markers as Predictors of TB-associated Immune Reconstitution Inflammatory Syndrome in HIV/TB Co-infected Persons in Thailand. AIDS Research and Human Retroviruses 2009;25:1083-9.

OFFICE INFORMATION:

Department of Medicine

Division of Infectious Diseases

630 West 168th Street, Box 82

New York, NY 10032

Tel: 212-305-7185 / 212-570-3081

Fax: 212-305-7290

E-mail: hvt2106@columbia.edu

 

 
 


http://www.cumc.columbia.edu/dept/id/images/spacer.gif

NAME: Barbara Taylor, MD

ACADEMIC TITLE:
Instructor in Clinical Medicine, Columbia University College of Physicians & Surgeons

Assistant Professor of Infectious Diseases, University of Texas Health Science Center San Antonio

EDUCATION:
Princeton University, A.B., 1995
Harvard Medical School, MD, 2001
Columbia University Mailman School of Public Health, MS in Epidemiology, 2009

SPECIALTY: HIV treatment outcomes in underserved and Spanish-speaking populations

RESEARCH SUMMARY: Dr. Taylor conducts mixed methods research to identify barriers to care and improve outcomes for underserved people living with HIV in the U.S. and Latin America. She is particularly interested in structural barriers to HIV care, such as geographic mobility, and the intersection between HIV and other comorbidities, including diabetes, obesity, and cardiovascular disease. She is faculty at the University of Texas Health Science Center San Antonio and is adjunct faculty at the Columbia University College of Physicians & Surgeons and the University of Texas School of Public Health. She has ongoing research projects in New York, San Antonio, and the Dominican Republic. She also teaches in the global health curriculum at UT and Columbia, and cares for patients in the University Health System’s Downtown HIV treatment center, University Hospital, and the Audie Murphy Memorial VA Hospital in San Antonio.

SELECTED ABSTRACTS AND PUBLICATIONS:
Taylor BS, Reyes EV, Levine EA, Khan SZ, Garduño SL, Donastorg Y, Hammer SM, Brudney K, Hirsch JS. Patterns of Geographic Mobility Predict Barriers to Engagement in HIV Care and Antiretroviral Treatment Adherence. AIDS Patient Care & STDs. 2014 Jun;28(6):284-95.

Taylor BS, Liang Y, Garduno LS, Walter EA, Gerardi M, Anstead GM, Bullock D & Turner BJ. High Risk of Obesity and Weight Gain for HIV-Infected Uninsured Minorities. J Acquir Immune Defic Syndr 2014;65:e33-40.

Lanham HJ, Leykum LK, Taylor BS, McCannon CJ, Lindberg C, Lester RT. How complexity science can inform scale-up and spread in health care: Understanding the role of self-organization in variation across local contexts. Social Science & Medicine. 2013; 93:194-202.

Taylor BS, Garduño LS, Wammack L, Gerardi M, Walter E, Bullock D, Turner BJ. The San Antonio HIV Cohort (SAHIV): Assessing Quality of Care Measures for Hypertension and Dyslipidemia in an HIV Clinic. Journal of Investigative Medicine. 2012;60(1):412-13.

Taylor BS, Chiasson MA, Scheinmann R, Hirshfield R, Humberstone M, Remien RH, Wolitski R, Wong T. Results from Two Online Surveys Comparing Sexual Behaviors in Hispanic, Black, and White Men Who Have Sex With Men. AIDS and Behavior. 2012; 16(3):644-52.

Taylor BS, Hunt G, Abrams EJ, Coovadia A, Meyers TM, Sherman G, Strehlau R, Morris L, Kuhn L. Rapid development of antiretroviral drug resistance mutations in HIV-infected children initiating protease inhibitor-based therapy less than 2 years of age in South Africa. AIDS Res Human Retroviruses. 2011;27(9):945-56.

Myers J, Taylor BS, Rojas R, Reyes EV, Vaughan C, José L, Javier C, Franco Estévez R, Donastorg Y, Batista A, Coakley E, Lie Y, Hammer SM, Brudney K. Transmitted drug-resistance among antiretroviral naïve patients with established HIV-1 infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literature. AIDS Res Human Retroviruses. 2012;28(7):667-74.

Uhlemann AC, Dumortier C, Hafer C, Taylor BS, Sánchez E J, Rodriguez-Taveras C, Leon P, Rojas R, Olive C, Lowy FD. Molecular characterization of Staphylococcus aureus from outpatients in the Caribbean reveals the presence of pandemic clones. Eur J Clin Microbiol Infect Dis. 2012;31(4):505-11.

Bhat M, Dumortier C, Taylor B, Miller M, Vasquez G, Yunen J, Brudney K, Sánchez E. J, Leon C, Rodriguez-Taveras C, Rojas R, Lowy FD. Detection of Staphylococcus aureus ST398 in Northern Manhattan and the Dominican Republic. Emerging Infectious Diseases, 2009; 15(2):285-7.

Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The Challenge of HIV Subtype Diversity. New England Journal of Medicine. 2008; 358:1590-602. http://content.nejm.org/cgi/content/full/358/15/1590

OFFICE INFORMATION:
630 W 168th Street, Box 82
New York, New York 10032
Tel: 212-305-7185
Fax: 212-305-7290
E-mail: bs2026@columbia.edu

 

http://www.cumc.columbia.edu/dept/id/images/spacer.gif

NAME: Anne-Catrin Uhlemann, MD, PhD

ACADEMIC TITLE:
Florence Irving Assistant Professor of Medicine

EDUCATION:
Eberhard Karls University, Tubingen, Germany, MD
Eberhard Karls, University, Tubingen, Germany, Dr. Med
University of London, United Kingdom, PhD

SPECIALTY: Internal Medicine and Infectious Diseases

RESEARCH SUMMARY: Dr. Anne-Catrin Uhlemann is the Florence Irving Assistant Professor of Medicine in the Division of Infectious Diseases in the College of Physicians and Surgeons at Columbia University. Her laboratory investigates the evolution of bacterial pathogens such as Staphylococcus aureus and carbapenem-resistant Klebsiella pneumoniae.

S. aureus research: The past decade has witnessed a dramatic increase in S. aureus infections acquired from the community. Yet there remains a limited understanding of how these strains spread and subsequently become established and persist within communities. Our research is focused on identifying molecular mechanisms that allow epidemic S. aureus strains such as USA300 to successfully disseminate. This project uses a combined approach of whole-genome comparative sequencing of longitudinally collected samples, genetic manipulation, and functional studies on bacterial adhesion and survival. These molecular studies are informed by ongoing epidemiological studies on S. aureus transmission in the local community.

K. pneumoniae infections in transplant recipients: Infections with carbapenem-resistant Enterobacteriaceae (CRE) have emerged as an urgent threat to healthcare, the “category of highest concern” in the 2013 CDC antimicrobial threat report. These multi-drug resistant infections are associated with high mortality. Recipients of solid organ transplantation, in particular liver transplant recipients are at increased risk for CRE infections. While intestinal colonization with CREs has been proposed as a potential risk factor for infections during CRE outbreaks, its actual contribution to infection remains incompletely understood. Moreover, there is a fundamental gap in knowledge on how these antibiotic resistant organisms transition from colonization to infection within affected hosts. We have established a cohort study of patients undergoing liver transplantation in which we aim to investigate the contribution of colonization to subsequent CRE infection. The long-term goal of this project is to elucidate at the bacterial genome level how CRE infections emerge and spread. Understanding these processes is critical to developing intervention and real-time clinical monitoring approaches to limit the impact of CRE infections at an individual and population level.

SELECTED ABSTRACTS AND PUBLICATIONS:
Austin ED, Sullivan SB, Whittier S, Lowy FD, Uhlemann AC. Peripheral Intravenous Catheter Placement Is an Underrecognized Source of Staphylococcus aureus Bloodstream Infection. Open Forum Infect Dis. 2016 Apr 6;3(2):ofw072. eCollection 2016 Mar.

Gomez-Simmonds A, Hu Y, Sullivan SB, Wang Z, Whittier S, Uhlemann AC. Evidence from a New York City hospital of rising incidence of genetically diverse carbapenem-resistant Enterobacter cloacae and dominance of ST171, 2007 – 2014. J Antimicrob Chemother 2016; 71(8):2351-3.

Pereira MR, Uhlemann AC. The evolving threat of carbapenem-resistant infections after liver transplantation: The case of Acinetobacter baumannii. Liver Transpl. 2016 May;22(5):579-81.

Gomez-Simmonds A, Greenman M, Sullivan SB, Tanner JP, Sowash MG, Whittier S, Uhlemann AC. Population structure of Klebsiella pneumoniae causing bloodstream infections at a New York City tertiary care hospital: diversification of multidrug-resistant isolates. J Clin Microbiol 2015 Jul;53(7):2060-7.

Uhlemann AC, Dordel J, Knox JR, Raven K, Parkhill J, Holden MT, Peacock SJ, Lowy FD. Molecular tracing of the emergence, diversification and transmission of S. aureus sequence type 8 in a New York community. Proc Natl Acad Sci U S A 2014; 111(18):6738-43.

Sowash MG, Uhlemann AC. Community-associated methicillin-resistant Staphylococcus aureus case studies. Methods Mol Biol. 2014;1085:25-69. Review.

Uhlemann AC, Hafer C, Miko BA, Sowash MG, Sullivan SB, Shu Q, Lowy FD. Emergence of sequence type 398 as a community- and healthcare-associated methicillin-susceptible Staphylococcus aureus in Northern Manhattan. Clin Infect Dis 2013; 57:700-3.

Uhlemann AC, Porcella SF, Trivedi S, Sullivan SB, Hafer C, Kennedy AD, Barbian KD, McCarthy AJ, Street C, Hirschberg DL, Lipkin WI, Lindsay JA, DeLeo FR, Lowy FD. Identification of a highly transmissible animal-independent Staphylococcus aureus ST398 clone with distinct genomic and cell adhesion properties. mBio 2012; 3: e00027-12.

Uhlemann AC, Kennedy AD, Martens C, Porcella SF, Deleo FR, Lowy FD. Toward an understanding of the evolution of Staphylococcus aureus strain USA300 during colonization in community households. Genome Biol Evol 2012; 4:1275-85.

Hafer C, Lin Y, Kornblum J, Lowy FD, Uhlemann AC. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2012; 56:5845-51.

Uhlemann AC, Fidock DA. Loss of malarial susceptibility to artemisinin in Thailand. Lancet 2012 379(9830):1928-30.

Price RN*, Uhlemann AC*, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ, Nosten F and Krishna S. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. The Lancet 2004;364:438-47; *Co-first authors.

OFFICE INFORMATION:

Department of Medicine

Division of Infectious Diseases

630 West 168th Street, Box 82

New York, NY 10032

Tel: 212-305-7185

Fax: 212-305-7290

E-mail: au2110@cumc.columbia.edu

 

Michael Yin, MD, MS

NAME: Michael Yin, MD, MS

ACADEMIC TITLE:

Associate Professor of Medicine



EDUCATION:
Princeton University, BA, 1991
Columbia College of Physicians and Surgeons, MD, 1996
Columbia University Mailman School of Public Health, MS (Epidemiology), 2004

SPECIALTY: HIV therapy and metabolic complications

RESEARCH SUMMARY: Dr. Yin is an Associate Professor of Medicine in the Division of Infectious Diseases. His primary research focus is on the metabolic complications of HIV infection and antiretroviral therapy. He is the Principal Investigator of a NIAID-funded R01 to examine the effects of the menopausal transition on bone and muscle outcomes in HIV-infected women in the Women’s Interagency HIV study (WIHS), utilizing imaging and biomarker techniques, novelin vitrobone precursor cell assays and assessment of muscle mass, quality and functional performance. He is the Principal Investigator of a NIAID-funded R01 to examine the effects of the menopausal transition on bone and muscle outcomes in HIV-infected women in the Women’s Interagency HIV study (WIHS), utilizing imaging and biomarker techniques, novel in vitro bone precursor cell assays and assessment of muscle mass, quality and functional performance. He is the Co-Principal Investigator of a NICHD-funded R01 to examine bone health in perinatally HIV-infected children on antiretrovirals in South Africa. He is also an investigator in the AIDS Clinical Trials Group (ACTG), HIV Vaccine Trials Network (HVTN), and a member of Bone and Metabolic Working Groups for the WIHS, Veterans Aging Cohort Study (VACS), and ACTG.

SELECTED ABSTRACTS AND PUBLICATIONS:
Arpadi S, Shiau S, Strehlau R, Pinillos F, Patel F, Kuhn L, Coovadia A, Ramteke S, Kaufman JL, Yin MT. Efavirenz is associated with higher bone mass inSouth African children with HIV. AIDS 2016 Jul 16 [Epub ahead of print] PMI: 27427876.

Sharma A, Hoover DR, Shi Q, Holman S, Plankey MW, Wheeler AL, Weber K, Floris-Moore M, Bolivar HH, Vance DE, Mack WJ, Golub ET, Holstad M, Yin MT. Falls among middle-aged women in the Women’s Interagency HIV Study. Antiviral Therapy 2016, Jul 18 [Epub ahead of print] PMID: 27427794.

Manavalan JS, Apradi S, Tharmarajah S, Shah J, Zhang CA, Foca M, Neu N, Bell DL, Nishiyama K, Kousteni S, Yin MT. Abnormal bone acquisition with early-life HIV infection: role of immune activation and senescent osteogenic precursors. Journal of Bone and Mineral Research 2016 Jun 10 (Epub ahead of print). PMID: 27283956

Yin MT, Skanderson M, Shiau S, Harwood KE, Ascheim J, Rimland D, Gibert C, Rodriguez-Barradas M, Bedimo R, Womack J. “Fracture prediction with modified FRAX in older HIV+ and HIV- men” Journal of Acquired Immune Deficiency Syndrome 2016 Mar 19 (Epub ahead of print) PMID: 27003493

Sharma A, Shi Q, Hoover DR, Anastos K, Tien PC, Young M, Cohen MH, Golub ET, Gustafson D, Yin MT. Increased fracture incidence in middle-aged HIV-infected and uninfected women: updated results from the Women’s Interagency HIV Study. Journal of Acquired Immunodeficieny Syndrome 2015, Sept 1;70(1):54-61. PMID 26322667

Overton ET, Chan ES, Brown TT, Tebas P, McComsey GA, Tenorio A, Melbourne K, Napoli A, Ribaudo HJ, Yin MT. High-dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation: a prospective, randomized placebo-controlled trial for bone health in HIV-infected individuals. Annals of Internal Medicine 2015, 162(12):815-824. PMID: 26075752

Dong HV, Cortes YI, Shiau S, Yin MT. Osteoporosis and fractures in HIV/HCV-coinfection: a systemic review and meta-analysis, AIDS, 2014 28(14):2119-31. PMID: 24977441

Yin MT, Lund E, Shah J, Zhang CA, Foca M, Neu N, Nishiyama KK, Zhou B, Guo E, Nelson J, Bell D, Shane E, Arpadi SA. Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in life, AIDS 2013 28(3): 345-54. PMID: 24072196

Shiau S, Lund EC, Arpadi S, Yin MT, Incident fractures in HIV-infected individuals: a systematic review and meta-analysis, AIDS 2013; 27(12):1949-1957. PMID: 24126140

Yin MT, Kendall MA, Wu X, Tassiopoulos K, Hochberg M, Huang JS, Glesby MJ, Bolivar H, McComsey GA. Fractures after antiretroviral initiation: An analysis of the ACTG longitudinal linked randomized trial (ALLRT) study. AIDS 2012 26(17):2175-84. PMID: 22951635

Yin MT, Zhang CA, McMahon DJ, Ferris DC, Irani D, Colon I, Cermers S, Shane E. Higher rates of bone loss in postmenopausal HIV-infected women: A longitudinal study. Journal of Clinical Endocrinology and Metabolism 2012 97(2): 554-62. PMID 22090266

Yin MT, Modarresi R, Shane E, Santiago F, Ferris DC, McMahon DJ, Cremers S, Laurence J. Effects of HIV infection and antiretroviral therapy with ritonavir on bone turnover and osteoclast induction. Osteoporosis International 2011, 22(5): 1459-68. PMID: 20683705

Yin MT, Lu D, Cremers S, Tien PC, Cohen MH, Shi Q, Shane E, Golub ET, Anastos K. Short-term bone loss in HIV-infected premenopausal women. Journal of Acquired Immune Deficiency Syndrome, 2010 53(2): 202-8, PMID 19890216

Yin MT, McMahon D, Ferris D, Zhang C, Shu A, Staron R, Colon I, Laurence J, Dobkin J, Hammer S, Shane E. Low bone mass and high bone turnover in postmenopausal HIV-infected Women. Journal of Clinical Endocrinology and Metabolism 2010; 95(2):620-9 PMID: 19965927

OFFICE INFORMATION:
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Tel: 212-305-7185
Fax: 212-305-7290
E-mail: mty4@columbia.edu

 

Back to Top